Back to GetFilings.com




SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-K

 


 

FOR ANNUAL AND TRANSITION REPORTS

PURSUANT TO SECTIONS 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

(Mark One)

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2003

 

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from              to             

 

Commission File No. 000-30436

 


 

SCIQUEST, INC.

(Exact Name of Registrant as Specified in Its Charter)

 


 

Delaware   56-2127592

(State or Other Jurisdiction

of Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

 

5151 McCrimmon Parkway, Suite 216, Morrisville, North Carolina 27560

(Address of Principal Executive Offices) (Zip Code)

 

(919) 659-2100

(Registrant’s telephone number, including area code)

 


 

Securities registered pursuant to Section 12(b) of the Act:

 

None

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of Each Class


 

Name of Each Exchange on Which Registered


common stock, par value $0.001 per share   The NASDAQ National Market

 


 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.    Yes  x    No  ¨

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Exchange Act Rule 12b-2).    Yes  ¨    No  x

 

As of March 15, 2004, the aggregate market value of the common stock held by non-affiliates of the registrant was approximately $14,801,250.

 

As of March 15, 2004, there were 3,747,152 shares of common stock outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the registrant’s definitive proxy statement for its annual meeting of stockholders scheduled for June 16, 2004 are incorporated by reference into Part III of this Report.

 



PART I

 

Item 1. Business

 

Overview

 

SciQuest provides on-demand supplier relationship management solutions that integrate organizations with their suppliers to enable comprehensive spend management. Spend management is the ability to view and analyze all spending across an enterprise, thereby providing greater insight into purchasing functions and giving an organization control and visibility to allow it to manage spending more effectively. SciQuest’s solutions are targeted for the life sciences and higher education markets.

 

SciQuest’s suite of modular applications helps companies to automate the spend management process. These solutions facilitate a company’s purchasing functions by reducing redundant tasks throughout the cycle of finding, acquiring and managing goods, which can result in increased efficiency, reduced cost and increased insight into an organization’s buying patterns.

 

Many of the world’s leading pharmaceutical, biotechnology and academic organizations rely on our solutions such as Biogen Idec, GlaxoSmithKline, Pfizer, Roche, Schering-Plough, Arizona State University, Indiana University, University of Michigan and the University of Pennsylvania. SciQuest is headquartered in Research Triangle Park, North Carolina.

 

HigherMarkets and SelectSite are our registered trademarks. This report also includes trademarks, service marks and trade names of other companies.

 

Recent Events

 

In January 2004, University of Pennsylvania, a SciQuest customer since the third quarter of 2003, implemented our HigherMarkets Spend Director product with over 75 preferred suppliers representing approximately 68% of the University’s purchase order transactions.

 

In January 2004, we launched two new materials management modules — Chemical Manager and Supplies Manager — rounding out our suite of on-demand materials management modules.

 

In January 2004, we announced that Array BioPharma signed a multi-year license agreement for the Spend Director and Requisition Manager products.

 

In January 2004, we announced that Biogen Idec expanded its multi-year license agreement for Spend Director. It will use Spend Director to enable vendor catalogs and automate order delivery for its primary commodity areas including laboratory, office and maintenance, repair and operations supplies.

 

In January 2004, we announced that Schering-Plough Corporation signed a multi-year license agreement for the Spend Director product.

 

In February 2004, we announced that four of the world’s leading universities have extended multi-year agreements for our HigherMarkets procurement automation solution. Those universities consist of University of Notre Dame, Indiana University, The University of Edinburgh and The University of Nottingham.

 

In February 2004, the HigherMarkets for SCT Banner e-procurement solution was launched. This product enables the integration between e-procurement solutions, such as the SciQuest HigherMarkets product, and SunGard’s SCT Banner Finance, resulting in real-time data integration that promotes data integrity across the enterprise.

 

In March 2004, we announced the launch of Sourcing Manager, an additional module to our suite of on-demand supplier relationship management modules. Leveraging technology from Ion Wave Technologies, Sourcing Manager will allow procurement professionals to quickly create, issue, monitor and award informal quotes and formal bid requests.

 

Background

 

According to IDC Research, Supplier Relationship Management is defined as those solutions designed to handle sourcing, procurement, transaction processing, order management, and payment support functions, all of which are connected to create a single view of the spending levels at a company and how its purchasing activities are integrated into a supplier community that can be easily tracked, benchmarked, and analyzed. IDC Research expects the Supplier Relationship Management market to grow to $3.1 billion by 2007.

 

1


An increasingly popular approach to application development involves the concept of on-demand architecture. On-demand solutions are built on a Web-native, multi-tenant architecture (i.e., a single application instance serving multiple customers) that affords vendors economies of scale, allowing them to offer competitive functionality at low-cost, subscription-based pricing. Other benefits include:

 

  fewer IT resource requirements for customers;

 

  faster implementation; and

 

  lower annual subscription-based fee versus a larger upfront payment.

 

Many organizations have begun to recognize the value of moving beyond e-procurement and to realize the benefits of a completely integrated solution. According to Forrester Research, there are significant challenges for software providers to overcome, including:

 

  software integration capabilities to suppliers;

 

  ability to integrate into existing enterprise requirements planning or financial systems; and

 

  user adoption.

 

SciQuest Solutions

 

Our on-demand Supplier Relationship Management solutions are designed to help organizations to better integrate with their suppliers to enable comprehensive spend management for the life sciences and higher education markets. By delivering a suite of modular applications, we allow organizations to utilize a completely Web-based e-commerce environment while leveraging their existing technology investments such as enterprise requirements planning or financial systems. By integrating customers with their key suppliers through the SciQuest Supplier Network, these modular solutions reduce redundant tasks throughout the cycle of finding, acquiring and managing goods to increase efficiency, reduce cost and increase insight into an organization’s total spending patterns.

 

Materials management solutions are also an important component of our Supplier Relationship Management solutions in the life sciences and higher education markets. Failure to comply with the increasingly restrictive regulations on the tracking and reporting of chemicals from organizations such as the Environmental Protection Agency and the U.S. Department of Agriculture can result in severe penalties. By integrating materials management into their e-procurement solution, organizations are able to track chemicals, biologicals, and supplies from purchase to disposal to ensure regulatory compliance.

 

Our Supplier Relationship Management solutions enable our customers to:

 

Connect to Suppliers. By providing access to over 1,000 suppliers representing multiple commodities, the SciQuest Supplier Network offers users a single point of enablement for both catalog content and order delivery. The network provides access to a diverse array of commodities including office supplies, maintenance, repair and operation supplies, furniture, computer equipment and scientific lab supplies. Users of our supplier enablement products have the ability to manage their relationships with suppliers within the network in a variety of ways. For instance, users can configure catalogs to reflect the organization’s contracted pricing and promote preferred vendors to end users. These benefits include:

 

  enabling a critical mass of suppliers through the SciQuest Supplier Network;

 

  increasing purchasing efficiencies by promoting preferred vendors with organization-specific pricing and internal inventory;

 

  tracking orders in real-time;

 

  comparing products and attributes side-by-side through normalized supplier data; and

 

  checking product availability, both internally and externally.

 

Capture Transactions. Our solutions engage the entire enterprise in spend management by centralizing purchasing transactions from across the entire organization. End users access a Web-based, e-commerce shopping interface to select products and place accurate requisitions. Purchasing departments can use the same application to approve requisitions and manage purchase orders. All purchasing data is integrated with other enterprise systems, including financial applications and enterprise resource planning systems, to maintain the integrity of financial data. These benefits include:

 

  increasing user adoption through its user-friendly environment;

 

  increasing contract compliance as a critical mass of transactions are conducted through the solution; and

 

  increasing time and cost savings through significant process efficiencies.

 

Control Spend. By combining supplier enablement with enterprise adoption, our solutions enable a critical mass of transactions to promote cost savings, process efficiencies and spend visibility analysis of purchasing functions and trends through analytical tools and reports. These benefits include:

 

  facilitating end-users to make the best purchasing decisions for the organization by electronically enabling all of their suppliers and integrating the entire procurement process;

 

2


  viewing complete data throughout the entire transaction process by means of robust reporting capabilities;

 

  promoting preferred providers to end-users to increase contract compliance; and

 

  increasing productivity by eliminating the traditional paper process.

 

Manage Risk. By integrating our materials management solutions into their e-procurement solution, organizations can manage all types of materials from purchase to disposal, including chemicals, biologicals and supplies. These benefits include:

 

  minimizing risk and ensuring regulatory compliance by tracking chemicals and biologicals from entry to disposal;

 

  tracking ordered items through an easy-to-use interface and creating containers of chemical substances with all the necessary information for inventory tracking;

 

  reducing maverick spending by avoiding purchases of substances already in inventory;

 

  finding substances and containers through robust structure and substructure searching tools; and

 

  adding containers directly from a purchase order to inventory.

 

Products and Services

 

SciQuest’s suite of modular applications helps to automate each step in the spend management process. When used with the SciQuest Supplier Network, these solutions facilitate a company’s purchasing functions by reducing redundant tasks throughout the cycle of finding, acquiring and managing goods, which can result in increased efficiency, reduced cost and greater insight into purchasing functions.

 

Our products deliver value at each stage of the cycle:

 

Find:

 

Spend Director and SciQuest Supplier Network. To maximize return on procurement investments, organizations must satisfy user needs while positively influencing purchasing behavior. Adding suppliers is not enough. To promote significant efficiencies, an organization must be able to enable, configure and deliver a critical mass of supplier content using a platform that promotes contract compliance while providing the optimal buying experience for end users. Spend Director is a Web-based, multi-commodity supplier enablement solution designed to enhance existing procurement systems to increase on-contract spending and improve enterprise-wide productivity.

 

Enabling a critical mass of supplier catalog content is crucial to maximizing user adoption, purchasing efficiency and access to spending data within a procurement system. The SciQuest Supplier Network offers an organization instant access to product information from over 1,000 scientific, medical, maintenance, repair and operations, office, information technology and other suppliers who participate in the SciQuest Supplier Network. This content and connectivity offers compelling benefits for organizations seeking to:

 

  Improve productivity. Spend Director aggregates product information from approved suppliers into one searchable Web interface, eliminating time-consuming searches through paper catalogs. Once needed supplies are identified, online requisition and order tracking minimize time spent by researchers on administrative tasks.

 

  Increase on-contract spending. Spend Director’s advanced administrative functionality allows procurement professionals to configure the purchasing experience for researchers, enabling them to showcase products from preferred suppliers.

 

Acquire:

 

SelectSite and HigherMarkets. SciQuest’s solutions, SelectSite for Life Sciences and HigherMarkets for Higher Education, are industry specific purchasing automation solutions that empower organizations with the tools they need to create an efficient, paperless procurement process. As the hubs for organizational purchasing activity, procurement departments need integrated technology that offers a holistic view of spending.

 

SelectSite is a modular suite of procurement automation solutions designed to reduce costs, improve productivity and increase insight into enterprise-wide spending. SelectSite’s hosted, flexible architecture enables organizations to design tailored solutions that work with existing enterprise systems to achieve targeted objectives.

 

HigherMarkets is a modular suite of technology solutions for procurement and financial systems that can increase productivity, reduce costs and improve customer service. Built on the SelectSite technology platform, HigherMarkets’ hosted, flexible architecture consists of productivity modules that automate each step of the procurement process.

 

3


The SelectSite and HigherMarkets e-procurement products are hosted solutions that automate requisitioning, sourcing, approval routing and order management for purchasing professionals seeking to:

 

  Centralize and automate purchasing functions. SelectSite and HigherMarkets e-procurement solutions streamline the entire procurement process from requisitioning to payment processing, enabling purchasing departments to increase their throughput without adding personnel.

 

  Integrate with key enterprise systems. To gain efficiencies, an organization’s e-procurement solution must integrate with administrative, financial and inventory systems. We work with other technology providers to meet the unique integration needs of our targeted vertical markets.

 

  Pursue strategic sourcing initiatives. Automating manual processes and redundant paperwork reduces purchasing costs while freeing procurement professionals to pursue strategic sourcing initiatives such as identifying new suppliers and negotiating contracts. Using in-depth reports, purchasing executives can measure return on investment and the effectiveness of procurement policies by analyzing the company’s buying patterns.

 

Manage:

 

Materials Management Modules and Enterprise Products for Reagent, Substance and Biologicals Management. Our deployed enterprise products and on-demand materials management inventory modules, which are integrated with our procurement products, track and monitor critical assets, such as chemicals, compounds, biologicals and supplies. These integrated offerings provide organizations with enhanced analytical capabilities with respect to their assets by allowing them to understand stock levels, reordering times and other key metrics. Our materials management modules include separate modules for biologicals, chemicals and supplies, whereas our enterprise products facilitates management of chemicals, substance management and biologicals. Our materials management products enable research organizations to:

 

  Leverage internal assets. Information about commercial and proprietary assets is consolidated and made available to laboratory managers and researchers via Web-based interfaces. Research teams across the hall or across the globe can access and order from the entire inventory of available compounds, substances and biologicals. By having increased access and analytical capabilities into their internal inventories, organizations are able to make better purchasing and materials management decisions.

 

  Minimize risks. Once received into the stockroom, reagents are logged into the inventory management system where hazardous materials are flagged. As these materials are checked out of the system by researchers, facilities managers are able to monitor usage and quickly assess potential occupational risks.

 

  Maintain compliance. Environmental, health and safety regulations require laboratories to submit detailed records of chemicals and reagent usage. Our materials management solutions streamline the process of maintaining compliance by providing real-time inventory information and automated reporting.

 

Professional Services:

 

Our Global Professional Services team provides technical consulting, project management, integration and training services to rapidly deploy our solutions. Through our established implementation methodology, clients have the ability to enhance their return on investment and complete implementations in scope, on time and on budget. We offer a solution specification, configuration and deployment process resulting in a solution that addresses specific client needs including risk management, tightly controlled project scope, phased implementation, knowledge transfer to end users, and standards-based, open solutions. Our methodology benefits clients seeking to:

 

  Avoid costly and time-consuming changes. Thorough, up-front planning of solution configuration options, feature extensions and integration avoids costly and time-consuming changes later in the project and reveals opportunities that might otherwise be lost.

 

  Increase success rate and ROI. Involvement of key users from the project outset increases the success rate and return on investment.

 

  Ensure cohesive implementation. Involvement of other solution providers allows for early identification of integration needs, project dependencies, project risks and development of a cohesive end-to-end project plan.

 

4


Strategic Goals

 

We are dedicated to enabling organizations to increase efficiency and reduce costs through increased control over their purchasing functions by helping them find and acquire resources and manage the lifecycle of critical assets. We intend to accomplish this through the following strategic goals as an organization:

 

Generate Revenue Growth. To achieve our revenue objectives, our sales and marketing teams must effectively sell our current products to new customers and find opportunities to cross-sell new or additional products to existing customers. We have been actively recruiting and training new sales professionals to achieve these objectives. We have structured compensation packages that motivate our sales organization to sell products that can be delivered in a timely and profitable manner.

 

Continue to Create Value for Customers by Delivering Quality Products and Services That Meet Their Needs. Effective product development and customer service are critical components to our success. We have implemented a disciplined, systematic approach to releasing new versions of our software to provide enhanced functionality requested by customers while optimizing our development resources. Development resources for future enhancements are allocated, in part, by the historical and future budgeted revenue of each product. Our customer support organization reports directly into the development organization. This reporting structure allows for rapid feedback between our customers and our product developers. We consistently measure and assess our professional services organization on the quality and value of the services they provide, such as technical consulting, project management, integration and training services.

 

Expand Our Product Portfolio. Customer feedback drives our development process. We use customer data and input to develop features and functions to enhance our existing products, as well as to provide a source of ideas for new products. We are analyzing our core technologies to identify additional ways to leverage our key strengths into new market opportunities. We continue to explore other possibilities for expanding our product portfolio and distribution network, including acquisitions, joint ventures and channel relationships. We are seeking acquisition opportunities where we can simultaneously grow revenues, eliminate redundant overhead, leverage acquired assets effectively and positively impact our path to profitability. We are seeking relationship opportunities where we can expand the market awareness of our products by leveraging the installed customer bases and marketing and sales channels of other organizations.

 

Create Value for Shareholders. For SciQuest to create long-term sustainable shareholder value, we must remain focused on expense control and invest in activities that will generate tangible return on investments. We consistently review our plans and progress to determine if our assets are being utilized for their best and highest value.

 

Sales & Marketing

 

Market Positioning. In the fourth quarter of 2003, we launched our new market positioning to articulate the value of our technology solutions. This new branding – centered on Supplier Relationship Management – has generated interest from industry analysts, trade journals, existing customers and prospects. We have engaged a public relations firm to assist in further positioning SciQuest as a thought leader in this market sector. Thus far, this market positioning has resulted in speaking invitations, feature articles in respected trade journals and unsolicited reports from industry analysts.

 

Life Sciences and Higher Education Markets. For over two years, we have concentrated our direct and channel marketing efforts toward two distinct markets – Life Sciences and Higher Education. While these markets operate on vastly different business models, their operating principles and procurement needs are quite similar, rendering our solutions a strong fit for both. The Life Sciences market leverages our strength and expertise in the procurement of scientific goods to provide a strong foundation for organization-wide spend management. We service the procurement and materials management needs of over 20 life science organizations. With a North American-based market of over 700 life science firms, we are well positioned for additional growth in this segment. For the Higher Education market, we provide university-wide procurement solutions that offer the ability to purchase goods across a variety of commodities. Many of our higher education clients are large, research-oriented universities with teaching hospitals and significant research functions. Similar to their life science counterparts, these organizations leverage our strength in the procurement of goods from the fragmented sciences industry to automate and monitor their university spending. We service nearly 20 higher education customers. With a United States-based market of over 4,000 private and public universities, our goal is to achieve continued penetration into this market segment.

 

Direct Sales Force and Indirect Sales Channels. Our direct sales force is empowered with a customer relationship management application, vertically-aligned marketing materials, and aggressive lead generation activities through tradeshows, speaking opportunities and media coverage. We also strive to expand our indirect sales channels through relationships with industry-respected companies such as SCT and the E&I Cooperative. We believe that these indirect sales channels, along with our direct sales force and the sales and marketing momentum generated in the latter half of 2003, will drive market awareness and sales opportunities for SciQuest throughout 2004.

 

As of December 31, 2003, we had 20 people in our sales and marketing group.

 

5


Technology

 

We have incorporated Rapid Application Development standards into our software product development methodologies. These standards are based on tried-and-true principles that focus intensely on customer and end-user perspectives. Rapid Application Development is the merger of structured prototyping and joint application development techniques leveraged to accelerate systems development. Rapid Application Development techniques allow our product teams to revolve their efforts around collaborative and timely customer input while achieving large gains in predictability, productivity and quality.

 

We leverage commercially available operating systems, data management systems, application services and scalable, distributed infrastructure. These industry standards are designed to ensure that our solutions are supported by an operating platform that provides for a high level of availability, increased speed-to-market and rapid, customer-focused growth. We have implemented standard practices in the areas of development, deployment, production control, administration and monitoring that include:

 

  version management;

 

  multiple, segmented development, test, staging and production environments;

 

  automated regression testing;

 

  load & stress testing;

 

  QA processes and procedures;

 

  application and database performance monitoring;

 

  application level error tracing;

 

  standardized development environment for consistent and efficient application development; and

 

  architectural review and oversight.

 

Our product suite is designed for customer deployment through both released and on-demand products.

 

On-Demand Products. Our on-demand products are similarly built around an n-tiered architecture based on the Java 2 Enterprise Edition standard. Business logic is encapsulated in Java components, and user interfaces are dynamic, HTML-based, and are generated using Java Servlets and Java Server Pages. SciQuest hosts all web/application and database servers. The customer is solely responsible for providing a browser-based client environment, running Windows or Mac O/S with MS Internet Explorer 5.5 sp2 and above or Netscape Navigator 6.2. Customers require no downloading of application code, plug-ins or applets from the server.

 

We own all of our hosted production servers and web site hardware. Our web applications run off of multiple redundant product application servers. Our production servers are located at a third-party network operating center located in Raleigh, North Carolina, which provides 24-hour systems support, as well as connectivity to all major Internet bandwidth via redundant high speed T-3 connections. The server and network architecture is designed to provide high speed and high-availability for the operation of our on-demand applications and communications.

 

We have contracted service level agreements with our Internet service provider, providing up time of 99.997% of network availability. This is accomplished through access to multiple Internet backbones with redundant network connections. On a nightly basis, a backup of the production environments and databases are performed and stored offsite in a vaulted location, which enables full business recovery. We regularly test the reliability of our fail over systems and have numerous contingency plans in place for business continuity. We utilize external monitoring and load testing tools to track the performance of our production environment.

 

Deployed Products. Our implemented products are designed around an n-tiered architecture based on the Java 2 Enterprise Edition standard. The main product component is built on three architectural building blocks, the Database Server, Web Application Server and the Client Machine. Business logic is encapsulated in Enterprise Java Bean components and user interfaces are dynamic HTML-based and are generated using Java Servlets and Java Server Pages.

 

  Our database server runs under Oracle 8i (version 8.1.6 or higher) supporting standard platforms that run that product.

 

  Our Web Application Server comes bundled with BEA WebLogic 5.1, a Java 2 Enterprise Edition compliant web application server. As configured, the product is compatible with Java 2, Java Servlet 2.2, Java Server Pages 1.1 and Enterprise Java Beans 1.1. Other Java 2 Enterprise Edition compliant application servers can be supported through customization using SciQuest services. The product supports Microsoft Windows NT 4.0 and Windows 2000 as application server operating systems. Support for other operating systems that are compatible with Oracle and WebLogic may also be available as needed.

 

  Our Client Machine is fully browser based, a true thin client, utilizing dynamic HTML and running on MS Internet Explorer 5.0. The product requires Windows 95 or NT 4.0 or Windows 2000 with a 400MHz P3 processor with 64MB of memory. Clients require no downloading of application code or applets from the server, except for those dispensary workstations that are integrated with balances for weighing operations. These workstations require a single applet, which is downloaded from the server.

 

6


As of December 31, 2003, we had 58 professionals in our development group, which consists of information technology professionals, content management professionals and our Global Professional Services group. Development expenses were $11.3 million in 2001, $7.7 million in 2002 and $4.9 million in 2003.

 

Intellectual Property

 

We rely on a combination of trade secret, copyright and trademark laws, license agreements, nondisclosure and other contractual provisions and technical measures to protect our proprietary rights in our products, technology and processes. We pursue the registration of our trademarks in the United States and internationally, however, we may not be able to secure adequate protection for our trademarks in the United States and other countries. SCIQUEST.COM and SELECTSITE are our trademarks in the United States, which are registered with the U.S. Trademark Office. We have applied for registration of the mark HIGHERMARKETS in the United States. The mark SCIQUEST is registered with the Community Trademark Office and in Switzerland. Our software technology is not patented and existing copyright laws offer only limited practical protection. We cannot guarantee that the legal protections on which we rely will be adequate to prevent misappropriation of our technology. Moreover, these protections do not prevent independent third-party development of competitive products or services. Furthermore, the validity, enforceability and scope of protection of intellectual property in internet-related industries are uncertain and still evolving. The laws of some foreign countries do not protect intellectual property to the same extent, as do the laws of the United States. We believe our products, trademarks and other proprietary rights do not infringe upon the proprietary rights of third parties. However, we cannot provide any guarantees about the third-party products sold to customers using our technology, services or products or that third parties will not assert infringement claims against us in the future or that any such assertion will not require us to enter into a license agreement or royalty agreement with the party asserting a claim. If the third-party products purchased by customers using our technology, services or products infringe the proprietary rights of third parties, we may be deemed to infringe those rights by selling such products. Even the successful defense of an infringement claim could result in substantial costs and diversion of our management’s efforts.

 

We intend to license a significant portion of our transaction fulfillment system from third parties. These licenses may not be available to us on favorable terms in the future. If we fail to obtain necessary licenses on favorable terms, it could have a material adverse effect on our business operations.

 

We also resell third-party applications to our customers. If these applications were found to infringe on the intellectual property rights of others and acceptable alternatives are not available, this may have a material adverse effect on our business.

 

Competition

 

The market for providing technology and services for organizations and their suppliers is fragmented, rapidly evolving and intensely competitive. Our primary competition includes the following:

 

Existing Processes and Internal Legacy Systems. Many research organizations and suppliers have deployed internal resources and systems or may be using existing external technology and service partners to provide for their technology and services solutions. Organizations with limited budgets for information technology may continue using existing solutions, thereby postponing upgrades or installations of new systems.

 

Enterprise Software Providers. A number of enterprise software providers have established technologies, solutions, and customer relationships that provide alternative choices for our potential customers.

 

Consultants and Custom Programming Providers. Research-intensive organizations may choose to use technology consultants or other resources to create customized technology solutions to meet their procurement needs.

 

Suppliers’ E-Commerce Initiatives. Many suppliers and distributors have developed their own e-commerce enabled web sites. These scientific suppliers’ online services provide partial solutions that may provide an alternative to our electronic content sourcing and procurement solutions.

 

We believe that companies in this market compete primarily on the basis of brand recognition, number and quality of product offerings, price, ease of use, and customer service and fulfillment capabilities.

 

Competition is likely to intensify as the Supplier Relationship Management market matures. As competitive conditions intensify, competitors may: enter into strategic or commercial relationships with larger, more established and well-financed companies; devote greater resources to marketing and promotional campaigns; secure exclusive arrangements with customers that impede our sales; and devote substantially more resources to product development.

 

7


Our current and potential competitors’ technology and solutions may achieve greater market acceptance than ours. Many existing and potential competitors have longer operating histories in the pharmaceutical and biotechnology industry, greater name recognition, larger customer bases and greater financial, technical and market resources.

 

In addition, new technologies and the expansion of existing technologies may increase competitive pressures. As a result of increased competition, we may experience reduced revenues and operating margins, as well as loss of market share and brand recognition. We cannot be certain that we will be able to compete successfully against current and future competitors and competition could have a material adverse effect on our revenue growth and earnings.

 

Employees

 

As of December 31, 2003, we had 89 full-time employees. None of our employees are covered by a collective bargaining agreement. We consider our relations with our employees to be good.

 

In March 2003, we initiated a reduction in the number of our full-time employees by approximately 50. These reductions were made in order to reduce our overhead costs in 2003 and future years. These reductions affected substantially all departments and were completed by the end of the second quarter of 2003.

 

Executive Officers

 

Our executive officers and their ages as of December 31, 2003 were as follows:

 

Name


     Age

    

Position


Stephen J. Wiehe

     40      Chief Executive Officer and Director

James B. Duke

     40      Chief Operating Officer, Products and Strategy

Kerry S. May

     56      Vice President, Worldwide Sales

James J. Scheuer

     56      Chief Financial Officer

 

Stephen J. Wiehe has served as our Chief Executive Officer and as a Director since February 2001. From June 2000 to February 2001, Mr. Wiehe served as Senior Director - Strategic Investments & Mergers and Acquisitions at SAS Institute. From October 1999 to June 2000, Mr. Wiehe served as President and Chief Executive Officer of DataFlux Corporation, which was acquired by SAS Institute. From June 1998 to October 1999, Mr. Wiehe served as Managing Director/Europe and senior executive vice president for SunGard Treasury Systems, a division of SunGard Data Systems, Inc (NYSE: SDS). From June 1996 to June 1998, Mr. Wiehe served as President and Chief Executive Officer of Multinational Computer Models, Inc., which was sold to SunGard Data Systems in 1998. Mr. Wiehe began his career with the General Electric Company. Mr. Wiehe graduated from its Financial Management Program with honors and became treasurer of GE Plastics. Mr. Wiehe is a graduate of the University of Kentucky.

 

James B. Duke has served as our Chief Operating Officer since April 2003. From February 2001 to April 2003, Mr. Duke also served as Vice President of Products and Strategy. From March 2000 to February 2001, Mr. Duke served as Chief Information Officer of BuildNet, Inc., a solutions provider for the construction materials industry. His prior experiences include roles as Vice President of Sales and Marketing at GE Capital Mortgage in 1999, Group Vice President for technology and alternative channels for First Citizens Bank from 1995 to 1999, and as a Management Consultant with McKinsey & Co. from 1992 to 1995. A graduate of Duke University, Mr. Duke also has a Masters degree from MIT’s Sloan School of Management.

 

Kerry S. May has served as our Vice President of Worldwide Sales since August 2002. Prior to joining SciQuest, Mr. May was Vice President of Worldwide Sales with DataDirect Technologies/Merant. Previously, Mr. May served as Vice President and Director of Operations for SourceAlliance, LLC and 23 years in various executive positions with Motorola, Inc. including Vice President/National Sales Manager for the U.S. market and Director of Global Operations for e-Commerce and Customer Service. Mr. May holds an M.B.A. from Northwestern University and a B.S. degree in Business Administration from San Diego State University.

 

James J. Scheuer has served as our Chief Financial Officer since September 1998. From March 1996 to March 1998, Mr. Scheuer served as Chief Operating Officer and later Chief Financial Officer for Boise Marketing Services, Inc., a subsidiary of Boise Cascade Office Products Corporation, and its predecessor. From December 1989 to March 1996, Mr. Scheuer served as Senior Vice President—Group Executive/Chief Financial Officer of Hickory Farms, Inc. From 1970 to 1989, Mr. Scheuer was employed by Deloitte Haskins & Sells and was the partner in charge of its Jacksonville, Florida office from 1985 to 1989. Mr. Scheuer is a certified public accountant and received his B.A. in accounting from the University of Wisconsin—Oshkosh.

 

Mr. Scheuer resigned as our Chief Financial Officer as of February 13, 2004.

 

There are no family relationships between any of our executive officers.

 

8


Item 2. Properties

 

Our headquarters are located in Morrisville, North Carolina, where we currently lease approximately 93,000 square feet of office space. This lease expires in July 31, 2005. We have sublet approximately 27,000 square feet of this space over various terms through July 31, 2005. We expect these facilities to be sufficient for the foreseeable future.

 

We maintain an office in Newtown Square, Pennsylvania. The lease for approximately 39,000 square feet of space expires in March 2011. We have sublet approximately 11,000 square feet of this space until March 2011, subject to certain terms for earlier termination at the option of the subleasee. We expect this space will be sufficient for the foreseeable future.

 

We are seeking to sublet any excess office space at these locations.

 

Item 3. Legal Proceedings

 

SciQuest and three of its officers were named as defendants in a lawsuit filed on September 10, 2001 in the United States District Court, Southern District of New York, captioned Patricia Figuerido v. Sciquest.com, Inc, No. 01 CV 8467. The case subsequently was consolidated for pretrial purposes with approximately 1,000 other lawsuits filed against more than 300 other issuers, certain of their officers and directors, and the underwriters of their initial public offerings, under the caption In re Initial Public Offering Securities Litigation, 21 MC 92 (SAS). After the cases were consolidated, plaintiffs filed a Master Complaint and 309 consolidated amended complaints related to each issuer defendant’s offering. The consolidated amended complaint in In re Sciquest.com, Inc. Initial Public Offering Securities Litigation, No. 01 Civ. 7415, purports, on behalf of a putative class of purchasers of our common stock from our initial public offering through December 6, 2000, to state claims under the Securities Act of 1933 and under the Securities Exchange Act of 1934 against SciQuest and seven investment banking firms who either served as underwriters, or are the successors in interest to underwriters, of our initial public offering. Separate claims against the underwriters only, also have been brought under the Securities Act and the Exchange Act. The complaint alleges that the prospectus used in our initial public offering contained material misstatements or omissions regarding the underwriters’ allocation practices and compensation in connection with the initial public offering and also alleges that the underwriters manipulated the aftermarket for our common stock. In October 2002, the claims against the Company’s officers were dismissed without prejudice. In February 2003, the court denied SciQuest’s motion to dismiss the action against it. On July 1, 2003, a Special Committee of the Board acting on behalf of the Company authorized the Company to enter into a definitive settlement agreement to be prepared under the terms outlined in a Memorandum of Understanding. The anticipated settlement will be subject to court approval following notice to class members and a fairness hearing. Until final approval of the settlement by the court, we intend to continue our vigorous defense against the action that originally sought an unspecified amount of damages, together with interest, costs and attorneys’ fees.

 

Until the definitive settlement agreement is finalized and executed, we can provide no assurances with regard to the final outcome of this matter. Adverse judgments in this matter could have a material adverse effect on our consolidated financial position, liquidity or consolidated results of operations.

 

Item 4. Submission Of Matters to a Vote of Security Holders

 

Not applicable.

 

9


PART II

 

Item 5. Market for the Registrant’s Common Equity and Related Stockholder Matters

 

SciQuest’s common stock trades under the symbol “SQST”. Through October 10, 2002, our common stock was listed on the Nasdaq National Market. On October 11, 2002, we transferred the listing of our common stock to the Nasdaq SmallCap Market. In order to satisfy Nasdaq’s minimum listing maintenance requirements for both the Nasdaq National Market and the Nasdaq SmallCap Market, we effected a one-for-seven and one-half (7 1/2) reverse stock split on May 20, 2003. On July 21, 2003, we transferred the listing of our common stock to the Nasdaq National Market. The prices per share reflected in the table below have been adjusted to reflect the reverse stock split and represents the range of low and high closing sale prices for our common stock for the years ended December 31, 2002 and 2003 as reported by the Nasdaq National Market and the Nasdaq SmallCap Market, as applicable, for the quarters indicated:

 

     2002

   2003

Quarter Ended


   High Price

   Low Price

   High Price

   Low Price

March 31

   $ 16.20    $ 10.50    $ 5.55    $ 3.30

June 30

   $ 14.70    $ 4.95    $ 4.88    $ 3.60

September 30

   $ 7.13    $ 4.58    $ 4.91    $ 3.50

December 31

   $ 5.18    $ 3.15    $ 4.90    $ 3.10

 

The closing sale price of our common stock as reported by The Nasdaq Stock Market on March 15, 2004 was $3.95.

 

The number of shareholders of record of our common stock as of March 15, 2004, was approximately 326.

 

We have never declared or paid cash dividends on our capital stock and we do not anticipate declaring or paying any cash dividends for the foreseeable future. We currently expect to retain all earnings, if any, for investment in our business.

 

Recent Sales of Unregistered Securities

 

There have been no securities sold by us within the last year that were not registered under the Securities Act.

 

Equity Compensation Plan Information

 

The following table sets forth number of shares of our common stock authorized for issuance under equity compensation plans as of December 31, 2003.

 

Plan Category


  

Number of Securities
to be Issued Upon
Exercise of
Outstanding Options,
Warrants and

Rights


  

Weighted Average
Exercise Price of
Outstanding
Options,
Warrants and

Rights


  

Number of Securities
Remaining Available for
Future Issuance Under
Equity Compensation
Plans, Warrants and

Rights


Equity compensation plans approved by security holders

   681,604    $ 12.83    629,833

Equity compensation plans not approved by security holders

   —        —      —  
    
  

  

Total

   681,604    $ 12.83    629,833
    
  

  

 

10


Item 6. Selected Financial Data

 

SELECTED CONSOLIDATED FINANCIAL DATA

(In thousands, except per share data)

 

Our selected financial data set forth below should be read in conjunction with our financial statements and accompanying notes appearing elsewhere in this report and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” The historical statements of operations data for the years ended December 31, 2001, 2002 and 2003, and the historical balance sheet data as of December 31, 2002 and 2003 are derived from, and are qualified by reference to, our financial statements that are included herein, which have been audited by PricewaterhouseCoopers LLP. The historical statement of operations data for the years ended December 31, 1999 and 2000 and the balance sheet data as of December 31, 1999, 2000 and 2001 are derived from our audited financial statements not included in this report. Historical results are not necessarily indicative of results to be expected in the future.

 

     Year Ended December 31,

 
     1999

    2000

    2001

    2002

    2003

 

Statement of Operations Data:

                                        

Revenues:

                                        

License fees and other professional services

   $ 690     $ 6,297     $ 6,981     $ 6,521     $ 6,634  

E-commerce

     3,192       45,407       16,230       —         —   (a)
    


 


 


 


 


Total revenues

     3,882       51,704       23,211       6,521       6,634  
    


 


 


 


 


Cost of revenues

                                        

License fees and other professional services

     449       3,841       5,116       7,243       5,486  

E-commerce

     2,977       44,392       15,393       —         —   (a)
    


 


 


 


 


Total cost of revenues

     3,426       48,233       20,509       7,243       5,486  
    


 


 


 


 


Gross profit

     456       3,471       2,702       (722 )     1,148  
    


 


 


 


 


Operating expenses:

                                        

Development

     9,064       17,035       11,291       7,705       4,879 (b)

Sales and marketing

     19,522       20,073       11,492       4,331       4,398 (b)

General and administrative

     7,136       55,023       54,800       10,394       7,160  

Purchased in-process research and development

     —         700       —         —         —    

Restructuring

     —         2,202       10,650       2,900       1,282 (b)

Impairment of intangible assets

     —         —         —         7,156       —    
    


 


 


 


 


Total operating expenses

     35,722       95,033       88,233       32,486       17,719  
    


 


 


 


 


Operating loss

     (35,266 )     (91,562 )     (85,531 )     (33,208 )     (16,571 )

Net other income

     1,869       7,149       2,694       947       429  
    


 


 


 


 


Loss before income taxes, discontinued operations and cumulative effect of accounting change

     (33,397 )     (84,413 )     (82,837 )     (32,261 )     (16,142 )

Income tax benefit

     219       66       —         —         —    
    


 


 


 


 


Loss from continuing operations before cumulative effect of accounting change

     (33,178 )     (84,347 )     (82,837 )     (32,261 )     (16,142 )

Loss from discontinued operations

     —         —         —         (270 )     (448 )

Cumulative effect of accounting change for impairment of goodwill

     —         —         —         (38,257 )     —    
    


 


 


 


 


Net loss

     (33,178 )     (84,347 )     (82,837 )     (70,788 )     (16,590 )

Accretion of mandatorily redeemable preferred stock

     (79,289 )     —         —         —         —    
    


 


 


 


 


Net loss available to common stockholders

   $ (112,467 )   $ (84,347 )   $ (82,837 )   $ (70,788 )   $ (16,590 )
    


 


 


 


 


Net loss per common share—basic and diluted:

                                        

From continuing operations before cumulative effect of accounting change

   $ (135.72 )   $ (22.40 )   $ (21.48 )   $ (8.22 )   $ (4.23 )

Loss from discontinued operations

     —         —         —         (0.07 )     (0.12 )

Cumulative effect of accounting change

     —         —         —         (9.74 )     —    
    


 


 


 


 


Net loss per common share—basic and diluted

   $ (135.72 )   $ (22.40 )   $ (21.48 )   $ (18.03 )   $ (4.35 )
    


 


 


 


 


Weighted average common shares outstanding—basic and diluted

     829       3,766       3,856       3,926       3,813  

Balance Sheet Data:

                                        

Cash and cash equivalents

   $ 98,126     $ 20,163     $ 25,370     $ 11,460     $ 13,128  

Working capital

     119,983       55,473       34,031       18,279       9,522 (a), (b)

Total assets

     156,902       203,193       115,926       47,839       31,881  

Long-term liabilities

     1,257       1,524       1,188       1,863       2,313  

Stockholders’ equity

     149,819       187,125       107,186       37,223       19,625  

(a) We began recording revenues from e-commerce transactions on a net basis (i.e., as an agent) as of May 1, 2001. Subsequently during 2001, the e-commerce transaction processing business was transitioned to a software and related services business model. See Revenue Recognition in Note 2 to our financial statements.
(b) In November 2000, June 2001 and January 2003, we implemented restructuring plans that would eliminate certain unprofitable business lines and over one-half of our employees located in the U.S. (see Note 16).

 

11


Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion should be read in conjunction with the consolidated financial statements and accompanying notes, which appear elsewhere in this report.

 

Some of the statements contained in this Management’s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report contain forward-looking information. You can identify these statements by forward-looking words such as “expect,” “anticipate,” “believe,” “goal,” “plan,” “intend,” “estimate,” “predict,” “project,” “potential,” “continue,” “may,” “will,” and “should” or similar words. They include statements concerning:

 

  our strategic goals;

 

  future sales opportunities;

 

  future growth of the Supplier Relationship Management market;

 

  expansion of our product and service offerings;

 

  future sources of revenues;

 

  future development expenses;

 

  future sales and marketing expenses;

 

  future general and administrative expenses;

 

  future non-cash stock-based customer acquisition costs;

 

  future operating expenses;

 

  future interest income;

 

  future cash flows;

 

  future operating losses;

 

  future licensing of software from third parties;

 

  future effects of our contractual obligations and other off-balance sheet arrangements;

 

  future revenue from a limited number of large customers;

 

  the length of our sales cycle;

 

  the sufficiency of our current facilities;

 

  our international expansion;

 

  results of our marketing efforts;

 

  future competition;

 

  future acquisition activity;

 

  future payment of dividends; and

 

  the adequacy of our existing liquidity and capital resources.

 

You should be aware that these statements are subject to known and unknown risks, uncertainties and other factors, including those discussed in the section entitled “Factors That May Affect Future Results,” that could cause the actual results to differ materially from those suggested by the forward-looking statements.

 

12


Overview

 

SciQuest provides on-demand supplier relationship management solutions that integrate organizations with their suppliers to enable comprehensive spend management. Spend management is the ability to view and analyze all spending across an enterprise, thereby providing greater insight into purchasing functions and giving an organization control and visibility to allow it to manage spending more effectively. SciQuest’s suite of modular applications helps companies to automate the spend management process. These solutions facilitate a company’s purchasing functions by reducing redundant tasks throughout the cycle of finding, acquiring and managing goods, which can result in increased efficiency, reduced cost and increased insight into an organization’s buying patterns. SciQuest’s solutions are targeted for the life sciences and higher education markets.

 

We were incorporated in November 1995 and commenced operations in January 1996. During 1996, we focused on developing our business model and the required technology. We did not begin to recognize any revenues until 1997. We launched our public e-commerce marketplace in 1999. Beginning with our acquisition of EMAX Solution Partners, Inc. (“EMAX”) in 2000, we have offered software products to the scientific products industry. In 2001, we ceased our order-processing services as we focused on providing software products and services.

 

We are continually evaluating our product offerings with regard to meeting our customers’ requirements and to acceptance in the marketplace. Also, we review the current and long-term profitability of each product. Our investment in each product is dependent upon its profitability potential. Periodically, we will decide to increase or decrease the investment, or even divest a product, based upon these reviews and analyses. Accordingly, in March 2003 we refocused our expenditures to support our procurement platform. As a result, we reduced costs in other areas. These cost reductions resulted in the elimination of approximately 50 full-time positions. In addition, we sold the Textco business unit to its original owners in the second quarter of 2003. During the third quarter of 2003, we also divested our interests in the BioSupplyNet and Groton NeoChem products.

 

Sources of Revenue

 

We generate revenues by charging license, subscription and maintenance fees for the use of our technology. We also offer professional services related to these solutions, for activities such as project implementation and training. In addition, we receive revenue from scientific supply manufacturers for converting their product catalogs into an electronic format, enhancing or enriching the data and distributing the information as directed by the suppliers.

 

Revenues consist of (1) sales of subscriptions to our hosted e-procurement solutions and materials management solutions, (2) sales of software licenses and fees for implementation, customization and maintenance services related to these software licenses, (3) sales of scientific products in e-commerce transactions originating on our web sites (from 1999 through 2001), (4) sales of scientific equipment (during 2000), (5) advertising revenues from our web sites, and (5) advertising revenues from the BioSupplyNet Source Book (through 2003), an annual catalog of industry suppliers. We expect that sales of subscriptions to our hosted e-procurement solutions and materials management solutions, software licenses and fees for implementation, customization and maintenance services related to these software licenses will be the primary sources of revenues in future periods.

 

We sell subscriptions to our hosted e-procurement solutions and materials management solutions. The implementation services and the total subscription fees are recognized ratably over the term of the agreement. We realize revenue from the sale of licenses to our delivered software products, the implementation and customization of our software products and the sale of maintenance and support contracts. We recognize revenues from the sale of licenses to our software products and implementation and customization that are deemed to be essential to the functionality of these software products, on a percentage-of-completion basis over the period of the customization and implementation services, which generally ranges from three to nine months. We recognize revenues from the sale of maintenance and support contracts ratably over the period of the maintenance and support agreements, which is typically twelve months. Revenues from the sale of standardized versions of software are recognized upon customer acceptance in accordance with Statement of Position 97-2, “Software Revenue Recognition.”

 

Advertising revenues are recognized ratably over the period in which the advertisement is displayed. Revenues from advertising included in the Source Book are recognized at the date the Source Book is published and distributed, which historically has been in the second quarter of the fiscal year. During 2003, we divested our investment in the net assets related to BioSupplyNet (including the Source Book), Groton NeoChem and Textco, Inc. As a result, we do not anticipate earning significant future revenue from advertising related to web sites or printed catalogues.

 

Restructuring

 

As part of a restructuring program announced in the first and second quarters of 2001, we reduced the number of full-time employees by approximately 100 and 130 people, respectively. The second quarter reduction was part of a restructuring program announced in June 2001, which included charges of approximately $1.6 million for separation benefits to those affected employees, $6.7 million of asset writedowns and approximately $2.4 million of other costs and lease obligations relating to the unprofitable business

 

13


lines to be eliminated. Due to the additional excess occupancy costs resulting from both an increase in the amount of unutilized rental space and an increase in the estimated number of months before receiving anticipated sublease proceeds because of the depressed local commercial real estate markets, we reevaluated the 2001 provision for excess office capacity and increased the charge for restructuring by $2.9 million during 2002.

 

During the first quarter of 2003, we began refocusing resources to support our procurement product platform and reducing costs in other areas, which resulted in a reduction of approximately 50 full-time positions through attrition and elimination by the end of the second quarter of 2003. The restructuring expense of $380,000 in the first quarter of 2003 represents the recognition of severance expense covering the 36 full-time positions that were eliminated. As a result of this restructuring, additional excess office space was identified. The associated additional excess lease cost of $650,000 was charged to restructuring expense in the second quarter of 2003. In addition, $140,000 was charged to restructuring expense in the third quarter of 2003 to reflect the actual terms of a sublease agreement signed during the third quarter that was previously estimated to begin at an earlier date. During the fourth quarter of 2003, $112,000 was charged to restructuring expense to reflect the adjusted terms of a sublease agreement resulting from bankruptcy proceedings of the subleasee.

 

Change in Business Procedure Affecting Revenue Reporting

 

Prior to May 1, 2001, we took legal title to the scientific products that we purchased from our suppliers and that, in turn, were sold to our customers in e-commerce transactions. As of May 1, 2001, we no longer took legal title to these products. Instead, we acted as an agent on behalf of the customer, and title passed directly from the supplier to the customer. This change allowed us to reduce or eliminate some of our general and administrative expenses, such as product insurance, regulatory compliance, sales tax filings and other related order-processing costs. We continued to be responsible for the collection of the receivables and to bear the resulting credit risk.

 

Since we acted as an agent for the customer and not as the primary obligor in the transaction for orders after May 1, 2001, we no longer recorded sales of scientific products and scientific equipment in e-commerce transactions on a gross basis. For each sale, we recognized revenue in the amount of the net commission that we earned for processing the transaction and/or payment for services. As a result of this change in our method of reporting revenue, we recorded much lower gross revenues from e-commerce transactions after May 1, 2001; however, our gross profit from e-commerce transactions was not materially affected although our gross margin as a percentage of related net revenue increased.

 

During the second half of 2001, we finalized the process of transitioning our business from an order-processing services model to a software and related services business model. Thus the level of e-commerce transactions was reduced and eventually eliminated during the last half of 2001.

 

Application of Critical Accounting Policies

 

Our consolidated financial statements are prepared in accordance with generally accepted accounting principles utilized in the U.S. Our significant accounting policies are fully described in Note 2 to the consolidated financial statements included under Item 8 of Form 10-K. However, certain of our accounting policies are particularly important to the portrayal of our financial position and results of operations and require a higher degree of judgment and complexity. While the estimates and judgments associated with the application of these policies may be affected by different assumptions and conditions, we believe the estimates and judgments associated with the reported amounts are appropriate in the circumstances. Our management has discussed each of the estimates and judgments described below with the Audit Committee of the Board of Directors and has received input from the members of the committee on these estimates and judgments. The following is a summary of our more significant accounting policies and how they impact our financial statements.

 

License fees and other professional services revenue. We sell software licenses and provide professional services to implement and configure the software to meet customer needs. We record the revenue from the sale of software licenses and custom development and implementation services under fixed-fee contracts using the percentage-of-completion method over the term of the development and implementation services. Therefore, the amount of revenue recognized is sensitive to the estimates to complete the remaining services. These estimates are reviewed and revised monthly. Estimates are based on project managers’ detailed implementation plans predicated on significant historical experience. If increases in projected costs to complete are sufficient to create an overall loss on an in-process contract, the entire estimated loss is charged against income in the period the estimated loss is initially identified. Revenue from the sale of standardized versions of our software is recorded upon customer acceptance. We also sell maintenance contracts, which are recognized over the term of the arrangement. In addition, we sell subscriptions to our hosted e-procurement solutions. The implementation services and the total subscription fees attributable to our hosted solutions are recognized ratably over the term of the agreement.

 

        Development costs. Development costs include expenses to develop, enhance, manage, monitor and operate our web sites and costs of managing and integrating data on our web sites and developing hosted software to be licensed. We capitalize internal use software development costs and amortize them over the estimated life of the related application, which generally ranges from three months to two years. The amount being capitalized and the amount amortized is dependent upon our ability to track and capture all application development costs associated with these multiple projects and our ability to estimate accurately their useful lives, respectively.

 

14


Capitalized software costs. Software development costs related to software products sold to customers are required to be capitalized beginning when a product’s technological feasibility has been established and ending when a product is available for general release to customers. These capitalized costs are then amortized over the estimated useful life of the related application, which is generally a period of two to four years. The amount being capitalized and the amount amortized is dependent upon our ability to track and capture all application development costs associated with these multiple projects and our ability to estimate accurately their useful lives, respectively.

 

Allowance for doubtful accounts. We bear all risk of loss on credit sales of products, licenses and professional services. The allowance for doubtful accounts at December 31, 2003 represents approximately 12% of total gross accounts receivable. Management’s estimate is developed from analysis of each individual customer account. Based on current economic conditions and historical experience, we believe that the allowance is adequate. However, if general economic conditions worsen, it could negatively impact the ability of customers to pay their obligations to us.

 

Deferred customer acquisition costs. Deferred customer acquisition costs relate to common stock warrants given to several key suppliers and buyers of scientific products. The amount of deferred customer acquisition costs is and will be adjusted in each reporting period based on changes in the fair value of the underlying common stock until the warrants are fully vested and non-forfeitable. Deferred customer acquisition costs will be amortized as a non-cash charge to sales and marketing expense over the term of the related contractual relationship using a cumulative catch-up method. The terms of the contractual relationships range from three to five years. The value of these warrants is adjusted each reporting period based upon the closing trading price of our common stock at each balance sheet date. As discussed above, changes in our closing trading price from one reporting period to the next will affect our amortization of these costs, and consequently, our results of operations. Because the amortization of these costs is dependent upon the trading price of our common stock, we cannot predict the future impact of this amortization on our results from operations. However, due to the reduced number of warrants outstanding as of December 31, 2003, we do not anticipate the amortization in future periods to be material.

 

Restructuring. As noted above, we previously announced two restructuring programs in prior years and one in the current year involving exiting certain unprofitable business lines. Various estimates developed from assumptions are involved in calculating the restructuring charges, especially related to lease obligations. Generally accepted accounting principles require that continuing lease obligations no longer providing economic benefit be calculated and offset by estimated sublease proceeds obtainable for the property. Estimating the potential sublease proceeds is dependent upon our ability to predict general and local economic market conditions.

 

Due to the additional excess occupancy costs resulting from both an increase in the amount of unutilized rental space and an increase in the estimated number of months before receiving anticipated sublease proceeds because of the depressed local commercial real estate markets, we reevaluated the 2001 provision for excess office capacity and increased the charge for restructuring by $2.9 million during 2002. As a result of a 2003 restructuring, additional excess office space was identified. The associated additional excess lease cost of $650,000 was charged to restructuring expense in the second quarter of 2003. In addition, $140,000 was charged to restructuring expense in the third quarter of 2003 to reflect the actual terms of a sublease agreement signed during the third quarter that was previously estimated to begin at an earlier date. During the fourth quarter of 2003, $112,000 was charged to restructuring expense to reflect the adjusted terms of a sublease agreement resulting from bankruptcy proceedings of the subleasee.

 

Goodwill and intangible asset valuation. We have historically evaluated the recoverability of goodwill and other intangible assets recorded on our balance sheet based on the estimated future undiscounted cash flows attributable to the assets or asset groups to which such goodwill and intangible assets relate. We test the carrying value of goodwill annually and identifiable intangible assets when a triggering event indicates the carrying value of those identifiable intangibles may exceed the anticipated undiscounted cash flows. We base the estimated future cash flows on actual operating budgets and other assumptions that management deems reasonable. However, because we transitioned our revenue model from e-commerce transactions to a software and related services model in 2001, there is limited history with which to base future estimated cash flows. If future operations are below our current expectations, we may need to revise these cash flow estimates downward, which may then require a writedown.

 

New accounting standards require a change in the methodology for measuring impairment by estimating fair value by using a discounted cash flow approach rather than an undiscounted cash flow approach (see Notes 2 and 7 to the Consolidated Financial Statements). The assumptions used in discounting cash flows attributable to the reporting units or asset groups to which goodwill and intangible assets relate, could have a material impact on our estimates of the recoverability and fair value of these assets and, in turn, impact the necessity and magnitude of a future impairment charge.

 

We adopted Statement of Financial Accounting Standards No. 142, “Goodwill and other Intangible Assets” (“SFAS No. 142”) effective January 1, 2002. This statement addresses accounting and reporting for acquired goodwill and intangible assets. In accordance with the transitional provisions of SFAS No. 142, we determined that the carrying value of goodwill and related assets exceeded their fair value. As a result, we recognized a charge to income of $38,257,357 ($9.74 per share), as the cumulative effect of a change in accounting principle during the first quarter of 2002. As of the end of each period presented, all of our intangible assets had definitive lives and were being amortized accordingly.

 

15


We evaluate the recoverability of our intangible assets subject to amortization in accordance with Statement of Financial Accounting Standards No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets,” (“SFAS No. 144”). SFAS No. 144 requires long-lived assets to be reviewed for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. An impairment is recognized in the event that the net book value of an asset exceeds the sum of the future undiscounted cash flows attributable to such asset or the business to which such asset relates and the net book value exceeds fair value. The impairment amount shall be measured as the amount by which the carrying amount of a long-lived asset (or asset group) exceeds its fair value.

 

In March 2000, we acquired all of the outstanding common and preferred stock of EMAX Solution Partners, Inc. and allocated $22,000,000 of the purchase price to trademarks. Subsequently, the value of the trademarks was being amortized to expense over a three-year period. During the first quarter of 2002, we discontinued utilizing the EMAX trademarks, and accordingly, determined that the carrying value of the trademarks had been impaired. As a result, we recognized a charge to income of $7,155,914, the unamortized balance at March 31, 2002, ($1.84 per share) in the first quarter of 2002.

 

Gross versus net e-commerce revenues presentation. As noted above, prior to May 1, 2001, we took legal title to the products that we purchased from our suppliers and that in turn, were sold to customers in e-commerce transactions. Because we were the primary obligor in these transactions, we recorded the revenue on a gross basis, whereby we recorded the price at which we sold the products to the customer as gross revenue and the amount we paid the supplier was recorded as cost of sales. Subsequent to May 1, 2001, when we stopped taking legal title to the product, we were no longer the primary obligor. Instead, we acted as an agent on behalf of the customer, and title passed directly from the supplier to the customer. Therefore, we no longer recorded the transaction revenue on a gross basis. For each sale, we recognized revenue in the amount of the net commission that we earned for processing the transaction. In addition, during 2001, we completed the transition away from the e-commerce transaction processing business model. As a result of the above, we recognized no revenues from e-commerce transactions after 2001.

 

Results of Operations

 

The following table sets forth certain operating data as a percentage of total revenues for the periods indicated.

 

     2001

    2002

    2003

 

Statement of Operations Data:

                  

Revenues:

                  

License fees and other professional services

   30.1 %   100.0 %   100.0 %

E-commerce

   69.9     —       —    
    

 

 

     100.0     100.0     100.0  
    

 

 

Cost of revenues:

                  

License fees and other professional services

   22.0     111.1     82.7  

E-commerce

   66.4     —       —    
    

 

 

     88.4     111.1     82.7  
    

 

 

Gross profit:

                  

License fees and other professional services

   8.1     (11.1 )   17.3  

E-commerce

   3.5     —       —    
    

 

 

     11.6     (11.1 )   17.3  
    

 

 

Operating expenses:

                  

Development

   48.6     118.1     73.6  

Sales and marketing

   49.5     66.4     66.3  

General and administrative

   236.1     159.4     107.9  

Restructuring

   45.9     44.5     19.3  

Impairment of intangible assets

   —       109.7     —    
    

 

 

Total operating expenses

   380.1     498.1     267.1  
    

 

 

Operating loss

   (368.5 )   (509.2 )   (249.8 )

Net other income

   11.6     14.5     6.5  
    

 

 

Loss from continuing operations before cumulative effect of accounting change

   (356.9 )   (494.7 )   (243.3 )

Loss from discontinued operations

   —       (4.1 )   (6.8 )

Cumulative effect of accounting change for impairment of goodwill

   —       (586.7 )   —    
    

 

 

Net loss

   (356.9 )%   (1,085.5 )%   (250.1 )%
    

 

 

 

16


Year Ended December 31, 2003 and 2002

 

Revenues

 

Revenues for the years ended December 31, 2003 and 2002 have been derived primarily from the subscriptions to our hosted e-procurement and materials management solutions and from the sale of licenses to our software products and the implementation and customization of our software products.

 

During the years ended December 31, 2003 and 2002, we recognized $6.6 million and $6.5 million, respectively, of revenue from fees from licenses and other professional services. These amounts include revenue related to advertising sold in the BioSupplyNet Source Book of $230,000 and $410,000, respectively, which is recorded annually when the Source Book is published. This decrease in the Source Book revenue is the result of lower levels of advertising sales due to reduced advertising budgets of the suppliers who normally purchase such advertising. The remaining revenue from fees from licenses and other professional services for the year ended December 31, 2003 increased to $6.4 million from $6.1 million for the year ended December 31, 2002.

 

During the year ended December 31, 2003, one customer accounted for 20% of gross revenues. There can be no assurance that this customer will continue to purchase at this level.

 

Cost of Revenues

 

Cost of revenues for license fees and other professional services primarily consist of personnel costs for employees who work directly on the development and implementation of customized electronic research solutions and who provide maintenance to customers as well as the amortization of capitalized software development costs. Cost of revenues relating to the BioSupplyNet Source Book consists primarily of printing, publishing and distribution of the Source Book.

 

Cost of revenues for license fees and other professional services for the years ended December 31, 2003 and 2002 was $5.5 million and $7.2 million, respectively, of which $3.0 million and $4.5 million, respectively, related to the amortization of acquired and capitalized software development costs. Also included in the cost of revenues for license fees and other professional services were the costs related to the BioSupplyNet Source Book of $200,000 and $190,000, during the years ending December 31, 2003 and 2002, respectively. The remaining cost of revenues for licenses and other professional services for the year ended December 31, 2003 decreased to $5.3 million from $7.1 million for the year ended December 31, 2002, primarily due to reduced amortization of acquired and capitalized software development costs.

 

Gross Profit

 

Gross profit increased to $1.1 million for the year ended December 31, 2003 from $(0.7) million for the year ended December 31, 2002. Gross profit from licenses and professional fees included gross profit from the BioSupplyNet Source Book of $30,000 and $220,000, during the year ended December 31, 2003 and 2002, respectively. The remaining gross profit for licenses and other professional services for the year ended December 31, 2003 increased to $1.1 million from $(0.9) million for the year ended December 31, 2002. This increase is primarily attributable to the decrease in amortization of acquired and capitalized software development costs relating to technology added from recent acquisitions and our Enterprise Substance Manager software to $3.0 million for the year ended December 31, 2003 from $4.5 million for the year ended December 31, 2002.

 

Operating Expenses

 

Development Expenses. Development expenses consist primarily of personnel and related costs to develop, operate and maintain our software, aggregate data and the amortization of capitalized development costs. Development costs decreased to $4.9 million for the year ended December 31, 2003 from $7.7 million for the year ended December 31, 2002. In 2002 and 2003, we began refocusing our development expenditures to our procurement and materials management product platform. As a result, this decrease is attributable to the reduction in development expenses in areas other than our procurement and materials management product platform. During the years ended December 31, 2003 and 2002, we capitalized approximately $2.0 million and $2.2 million, respectively, of certain costs related to software and hosted application development projects. We expect our development expenses to be comparable in 2004 as compared to 2003.

 

Included in development expenses is the amortization of non-cash stock-based employee compensation expense, which totaled approximately $64,000 and $280,000 for the years ended December 31, 2003 and 2002, respectively. This is primarily due to stock options that had been issued to employees with exercise prices less than fair value on the date of grant since December 31, 1999. Deferred compensation recorded due to the issuance of such stock options is charged to stock-based employee compensation expense over the vesting term of the options. The number of such stock options has been reduced due to past headcount reductions, resulting in reduced non-cash expense.

 

17


Sales and Marketing Expenses. Sales and marketing expenses consist primarily of operating expenses such as salaries and other related costs for sales and marketing personnel, travel expenses, public relations expenses and marketing materials as well as amortization of non-cash stock-based customer acquisition costs. Total sales and marketing expenses increased to $4.4 million for the year ended December 31, 2003 from $4.3 million for the year ended December 31, 2002. This increase resulted primarily from a credit of $(393,000) in 2002 related to the non-cash stock-based customer acquisition costs described below compared to a charge of $7,000 in 2003. Apart from this credit in 2002, the remaining expenses decreased primarily from a reduction in the number of sales and marketing personnel to market certain products and services.

 

Stock-based customer acquisition costs represent the amortization of deferred customer acquisition costs that were initially recorded in November 1999 upon the issuance of common stock warrants to key suppliers and customers. The value of these warrants is adjusted each reporting period based upon the closing trading price of our common stock at each balance sheet date. Decreases in our closing trading price from one reporting period to the next will likely result in a benefit, and increases in our closing trading price will likely result in charges to expense. Because the amortization of these costs is dependent upon the trading price of our common stock, the future amounts of this amortization will vary based on trading price fluctuations. During 2001 and the second half of 2002, the majority of these warrants were cancelled. Non-cash stock-based customer acquisition costs (benefit) for the year ended December 31, 2003 increased to approximately $7,000 from $(393,000) for the year ended December 31, 2002 and are expected to be minimal in the future due to the reduced number of warrants outstanding.

 

Also included in sales and marketing expense is the amortization of non-cash stock-based employee compensation expense, which totaled approximately $0 and $48,000 for the years ended December 31, 2003 and 2002, respectively. This is primarily due to stock options that had been issued to employees in our sales and marketing departments with exercise prices less than fair value on the date of grant. Deferred compensation recorded due to the issuance of such stock options is charged to stock-based employee compensation expense over the vesting term of the options. The number of such stock options has been reduced due to the recent headcount reductions, resulting in reduced non-cash expense.

 

We expect our sales and marketing expenses in 2004 to increase slightly compared to 2003, as we increase the focus of our sales and marketing efforts on our procurement product platform.

 

General and Administrative Expenses. General and administrative expenses consist primarily of personnel and related costs for our general corporate functions, including finance, accounting, legal, human resources, investor relations, facilities as well as the amortization of intangibles and non-cash stock-based employee compensation. Total general and administrative expenses decreased to $7.2 million for the year ended December 31, 2003 from $10.4 million for the year ended December 31, 2002.

 

Amortization of intangible assets decreased to approximately $73,000 from $1.8 million during the year ended December 31, 2003 and 2002, respectively. The 2002 amortization of $1.8 million related primarily to our March 2000 acquisition of EMAX Solutions. There was no amortization of intangible trademark assets during the year ended December 31, 2003 as a result of the discontinuance of the EMAX trademarks as discussed in Note 7 of the Consolidated Financial Statements.

 

Also included in general and administrative expenses is the amortization of non-cash stock-based employee compensation expense, which totaled $16,000 and $51,000 for the years ended December 31, 2003 and 2002, respectively. This is primarily due to stock options that had been issued to employees within our general corporate functions with exercise prices less than fair value on the date of grant. Deferred compensation recorded due to the issuance of such stock options is charged to stock-based employee compensation expense over the vesting term of the options. The number of such stock options has been reduced due to past headcount reductions, resulting in reduced non-cash expense.

 

We expect general and administrative expenses to be slightly lower in 2004 compared to the 2003 total due to the higher level of personnel employed during the first part of 2003.

 

Restructuring. During the first quarter of 2003, we began refocusing resources to support our procurement product platform and reducing costs in other areas, which resulted in an elimination of approximately 50 full-time positions by the end of the second quarter of 2003. This reduction in personnel resulted in the recognition of severance expense and additional excess office space. Also during 2003, new subleases and adjustments to previous subleases resulted in adjustments to the restructuring liability and charges to restructuring expense.

 

As part of a restructuring program announced in June 2001, the restructuring charge included approximately $2.4 million of other costs and lease obligations relating to the unprofitable business lines to be eliminated. During 2002, the restructuring was completed except for the lease obligations. Due to the additional excess occupancy costs resulting from both an increase in the amount of unutilized rental space and an increase in the estimated number of months before receiving anticipated sublease proceeds because of the depressed local commercial real estate markets, we reevaluated the 2001 provision for excess office capacity and increased the charge for restructuring by $2.9 million during 2002.

 

        Impairment of Intangible Assets. We evaluate the recoverability of our intangible assets subject to amortization in accordance with Statement of Financial Accounting Standards No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets” (“SFAS No. 144”). SFAS No. 144 requires long-lived assets to be reviewed for impairment whenever events or changes in circumstances

 

18


indicate that their carrying amount may not be recoverable. An impairment is recognized in the event that the net book value of an asset exceeds the sum of the future undiscounted cash flows attributable to such asset or the business to which such asset relates and its net book value exceeds fair value. The impairment amount is measured as the amount by which the carrying amount of a long-lived asset (asset group) exceeds its fair value.

 

In March 2000, we acquired all of the outstanding common and preferred stock of EMAX Solutions and allocated $22,000,000 of the purchase price to trademarks. Subsequently, we were amortizing the value of the trademarks to expense over a three-year period. During the first quarter of 2002, we discontinued utilizing the EMAX trademarks and, accordingly, determined that the carrying value of the trademarks had been impaired. As a result, we recognized a charge to income of $7,155,914, the unamortized balance at March 31, 2002, ($1.84 per share) in the first quarter of 2002 (see Note 7 of the Notes to the Consolidated Financial Statements for additional discussion). There were no impairments of other intangible assets during the year ended December 31, 2003.

 

Other Income (Expense)

 

Other income (expense) primarily consists of interest income earned on cash deposited in money market accounts and other short and long-term investments partially reduced by interest expense incurred on capital lease and debt obligations. Net other income (expense) decreased to approximately $429,000 for the year ended December 31, 2003 from approximately $947,000 for the year ended December 31, 2002. This decrease was primarily from reduced interest income resulting from our use of cash and investments to fund operations during 2002 and 2003 as well as a reduction in interest rates between the comparative periods. We expect net interest income to continue to be lower in 2004 than in 2003.

 

Loss from Discontinued Operations

 

During the second quarter of 2003, we sold Textco, Inc. As a result, we reclassified previously reported revenue and expense items from the respective lines in the Statement of Operations to Loss from Discontinued Operations.

 

The loss from operations was approximately $201,000 during the year ended December 31, 2003 compared to $270,000 during the year ended December 31, 2002. Revenues were approximately $244,000 and $700,000 for the year ended December 31, 2003 and 2002, respectively. The reduction in revenue is partially due to operating the business for only five months during 2003 as well as a significant sale during the second quarter of 2002 in the pharmaceutical industry. In addition, we recognized a loss on the sale of the unit of approximately $247,000 in the second quarter of 2003.

 

Cumulative Effect of Accounting Change

 

We adopted Statement of Financial Accounting Standards No. 142, “Goodwill and other Intangible Assets” (“SFAS No. 142”) effective January 1, 2002. This statement addresses accounting and reporting for acquired goodwill and intangible assets. In accordance with the transitional provisions of SFAS No. 142, we determined that the carrying value of goodwill and related assets exceeded their fair value. As a result, we recognized a charge to income of $38,257,357 ($9.74 per share) of goodwill impairment as the cumulative effect of a change in accounting principle during the first quarter of 2002. There was no cumulative effect of accounting change during the year ended December 31, 2003.

 

Net Loss

 

Net loss decreased to $16.6 million for the year ended December 31, 2003 from $70.8 million for the year ended December 31, 2002. The reduction in net loss was primarily due to not incurring any impairment of intangibles or cumulative effect of accounting change for goodwill impairment of $7,155,914 and $38,257,357, respectively, as had occurred during the year ended December 31, 2002.

 

Year Ended December 31, 2002 and 2001

 

Revenues

 

Revenues for the years ended December 31, 2002 and 2001 have been derived primarily from the sale of licenses to our software products, the implementation and customization of our software products and, during 2001, from the sale of scientific products and scientific equipment in e-commerce transactions.

 

During the years ended December 31, 2002 and 2001, we recognized $6.5 million and $7.0 million, respectively, of revenue from fees from licenses and other professional services. These amounts include revenue related to advertising sold in the BioSupplyNet Source Book of $410,000 and $650,000, respectively, which is recorded annually when the Source Book is published.

 

19


E-commerce transaction revenues were $16.2 million for the year ended December 31, 2001. As we previously discussed, effective May 1, 2001, we stopped taking legal title to products we purchased from our suppliers and, in turn, sold to our customers. As a result, for products sold after May 1, 2001, we recorded revenue as the net commission that we earned for processing the transaction. Therefore, revenues for the year ended December 31, 2001 were composed of sales prior to May 1, 2001, totaling $15.7 million, which were recorded on a gross basis and $0.5 million representing the commissions earned on transactions processed after May 1, 2001. The total value of scientific product transactions processed during the year ended December 31, 2001 was $25.7 million. There were no e-commerce transaction revenues in 2002.

 

During the year ended December 31, 2002, two customers accounted for 20% and 13%, respectively, of gross revenues. There can be no assurance that these customers will continue to purchase at these levels.

 

Cost of Revenues

 

Cost of revenues for license fees and other professional services primarily consist of personnel costs for employees who work directly on the development and implementation of customized electronic research solutions and who provide maintenance to customers as well as the amortization of capitalized software development costs. Cost of revenues relating to the BioSupplyNet Source Book consists primarily of printing, publishing and distribution of the Source Book. Cost of e-commerce revenues related to transactions for orders placed prior to May 1, 2001 primarily consists of the purchase price of scientific products sold in these transactions and related shipping costs for these products.

 

Cost of revenues for license fees and other professional services for the years ended December 31, 2002 and 2001 were $7.2 million and $5.1 million, respectively, of which $4.5 million and $2.7 million, respectively, related to the amortization of capitalized software development costs. Also included in the cost of revenues for license fees and other professional services were the costs related to the BioSupplyNet Source Book of $190,000 and $290,000, during the years ending December 31, 2002 and 2001, respectively.

 

Cost of e-commerce revenues was $15.4 million for the year ended December 31, 2001. We discontinued our order-processing services during the second half of 2001. Therefore, there were no costs of e-commerce revenues in 2002.

 

Gross Profit

 

Gross profit decreased to $(0.7) million for the year ended December 31, 2002 from $2.7 million for the year ended December 31, 2001.

 

Gross profit from licenses and professional fees was $(0.7) million and $1.9 million for the years ended December 31, 2002 and 2001, respectively, of which $(0.9) million and $1.5 million, respectively, related to license fees and $220,000 and $360,000, respectively, were derived from the Source Book. The reduction in gross margin is primarily attributable to increased amortization of acquired and capitalized software development costs due to technology added from recent acquisitions and our Enterprise Substance Manager software.

 

Gross profit on the sale of e-commerce revenues was $0.8 million for the year ended December 31, 2001, which represented approximately a 5.2% gross profit. There were no sales of scientific products in 2002.

 

Operating Expenses

 

Development Expenses. Development expenses consist primarily of personnel and related costs to develop, operate and maintain our software, aggregate data and the amortization of capitalized development costs. Development costs decreased to $7.7 million for the year ended December 31, 2002 from $11.3 million for the year ended December 31, 2001. This decrease resulted from decreased expenses required to develop our e-commerce fulfillment system and list suppliers’ products on our web sites as we transitioned out of the order processing business model. We reduced our development costs related to our e-commerce business as we focused on selling software and services. During the years ended December 31, 2002 and 2001, we capitalized approximately $2.3 million and $6.2 million, respectively, of certain costs related to software and web site development projects.

 

Included in development cost is the amortization of non-cash stock-based employee compensation expense, which totaled $0.3 million and $0.4 million for the years ended December 31, 2002 and 2001, respectively. This is primarily due to stock options that had been issued to employees with exercise prices less than fair value on the date of grant since December 31, 1999. Deferred compensation recorded due to the issuance of such stock options is charged to stock-based employee compensation expense over the vesting term of the options.

 

Sales and Marketing Expenses. Sales and marketing expenses consist primarily of salaries and other related costs for sales and marketing personnel, travel expenses, public relations expenses and marketing materials. Sales and marketing expenses decreased to

 

20


$4.3 million for the year ended December 31, 2002 from $11.5 million for the year ended December 31, 2001. This decrease resulted primarily from reducing the number of sales and marketing personnel to market our products and services and from reducing advertising and promotion expenses for our e-commerce marketplace and from a credit of $(0.4) million related to the non-cash stock-based customer acquisition costs described below. Sales and marketing expenses for years ended December 31, 2002 and 2001 include $0.1 million and $0.2 million, respectively, of amortization of non-cash stock-based employee compensation. Also included in sales and marketing expenses for the years ended December 31, 2002 and 2001 is amortization (benefit) expense of non-cash stock-based customer acquisition costs of ($0.4) million and $2.1 million, respectively.

 

Stock-based customer acquisition costs represent the amortization of deferred customer acquisition costs that were initially recorded in November 1999 upon the issuance of common stock warrants to key suppliers and customers. The value of these warrants is adjusted each reporting period based upon the closing trading price of our common stock at each balance sheet date. Decreases in our closing trading price from one reporting period to the next will likely result in a benefit, and increases in our closing trading price will likely result in charges to expense.

 

General and Administrative Expenses. General and administrative expenses consist primarily of personnel and related costs for our general corporate functions, including finance, accounting, legal, human resources, investor relations, facilities as well as amortization of intangibles and non-cash stock-based employee compensation. General and administrative expenses decreased to $10.4 million for the year ended December 31, 2002 from $54.8 million for the year ended December 31, 2001. General and administrative expenses in 2001 includes amortization of goodwill and other intangible assets of $39.6 million, as compared to $1.8 million of amortization of other intangible assets in 2002, relating primarily to our March 2000 acquisition of EMAX. There was no goodwill amortization during 2002 as a result of the change in accounting for goodwill as discussed in Note 7 of the Consolidated Financial Statements. As a result of the discontinued use of the EMAX trademarks, only $1.8 million of the related amortization was recorded in 2002 as discussed in Note 7 of the Consolidated Financial Statements. General and administrative expenses also include a charge of $0.1 million and $0.5 million relating to non-cash stock-based employee charges in the years ended December 31, 2002 and 2001, respectively. General and administrative expenses before these non-cash charges decreased by $6.2 million, primarily due to reduced personnel.

 

Restructuring. In June 2001, we announced a restructuring of our business to essentially eliminate outsourced procurement services. The restructuring included the elimination of certain unprofitable business lines and a resultant reduction in workforce of approximately half of the employees located in the United States. The total restructuring charge in 2001 was $10.7 million and included approximately $1.6 million for employee separation benefits, $6.7 million of assets and approximately $2.4 million of other costs and lease obligations relating to the unprofitable business lines to be eliminated. During 2002, we increased the charge for restructuring by $2.9 million to reflect the additional excess occupancy costs we anticipated incurring until we are able to sublet the excess office space.

 

Impairment of Intangible Assets. We evaluate the recoverability of our intangible assets subject to amortization in accordance with Statement of Financial Accounting Standards No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets” (“SFAS No. 144”). SFAS No. 144 requires long-lived assets to be reviewed for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. An impairment is recognized in the event that the net book value of an asset exceeds the sum of the future undiscounted cash flows attributable to such asset or the business to which such asset relates and its net book value exceeds fair value. The impairment amount is measured as the amount by which the carrying amount of a long-lived asset (asset group) exceeds its fair value.

 

In March 2000, we acquired all of the outstanding common and preferred stock of EMAX and allocated $22,000,000 of the purchase price to trademarks. Subsequently, we were amortizing the value of the trademarks to expense over a three-year period. During the first quarter of 2002, we discontinued utilizing the EMAX trademarks and, accordingly, determined that the carrying value of the trademarks had been impaired. As a result, we recognized a charge to income of $7,155,914, the unamortized balance at March 31, 2002, ($1.84 per share) in the first quarter of 2002 (see Note 7 of the Consolidated Financial Statements for additional discussion).

 

Other Income (Expense)

 

Other income (expense) primarily consists of interest income earned on cash deposited in money market accounts and other short and long-term investments partially reduced by interest expense incurred on capital lease and debt obligations. Net other income (expense) decreased to $0.9 million for the year ended December 31, 2002 from $2.7 million for the year ended December 31, 2001. This decrease was primarily from reduced interest income resulting from our use of cash and investments to fund operations during 2001 and 2002 as well as a reduction in interest rates between the comparative periods.

 

Loss from Discontinued Operations

 

During the second quarter of 2003, we sold Textco, Inc. As a result, we reclassified previously reported revenue and expense items from the respective lines in the Statement of Operations to Loss from Discontinued Operations.

 

21


The loss from operations was $270,000 during the year ended December 31, 2002. Revenues were approximately $700,000 for the year ended December 31, 2002. Since Textco, Inc. was not acquired until February 2002, there were no revenues or discontinued operations to report for the year ended December 31, 2001.

 

Cumulative Effect of Accounting Change

 

We adopted Statement of Financial Accounting Standards No. 142, “Goodwill and other Intangible Assets” (“SFAS No. 142”) effective January 1, 2002. This statement addresses accounting and reporting for acquired goodwill and intangible assets. In accordance with the transitional provisions of SFAS No. 142, we determined that the carrying value of goodwill and related assets exceeded their fair value. As a result, we recognized a charge to income of $38,257,357 ($9.74 per share) of goodwill impairment as the cumulative effect of a change in accounting principle during the first quarter of 2002.

 

Net Loss

 

Net loss decreased to $70.8 million for the year ended December 31, 2002 from $82.8 million for the year ended December 31, 2001.

 

Quarterly Results of Operations

 

The following is a table of our unaudited quarterly statement of operations data for each of the periods indicated. This information is unaudited, but in our opinion, has been prepared substantially on the same basis as our audited financial statements, which are included elsewhere in this report. All necessary adjustments, consisting only of normal recurring adjustments, have been included in these amounts to present fairly the unaudited quarterly results of operations. You should read this quarterly data in conjunction with our audited financial statements. You should not view the results of operations for any period as an indication of the results of operations for any future period.

 

     Quarter Ended

 
     2002

    2003

 
     Mar. 31

    June 30

    Sept. 30

    Dec. 31

    Mar. 31

    June 30

    Sept. 30

    Dec. 31

 

Revenues

   $ 1,622     $ 1,776     $ 1,531     $ 1,592     $ 1,688     $ 1,830     $ 1,491     $ 1,625  

Costs of revenues

     1,513       2,105       1,853       1,772       1,843       1,478       1,169       996  
    


 


 


 


 


 


 


 


Gross profit

     109       (329 )     (322 )     (180 )     (155 )     352       322       629  
    


 


 


 


 


 


 


 


Operating expenses:

                                                                

Development

     1,875       2,037       2,247       1,546       1,350       1,174       1,147       1,208  

Sales and marketing

     1,805       (76 )     1,183       1,419       1,253       962       1,010       1,173  

General and administrative

     3,843       1,738       2,038       2,775       2,365       1,912       1,495       1,388  

Restructuring

     —         —         —         2,900       380       650       140       112  

Impairment of intangible assets

     7,156       —         —         —         —         —         —         —    
    


 


 


 


 


 


 


 


Total operating expenses

     14,679       3,699       5,468       8,640       5,348       4,698       3,792       3,881  
    


 


 


 


 


 


 


 


Operating loss

     (14,570 )     (4,028 )     (5,790 )     (8,820 )     (5,503 )     (4,346 )     (3,470 )     (3,252 )

Net other income

     295       284       200       168       142       100       80       107  
    


 


 


 


 


 


 


 


Loss from continuing operations before cumulative effect of accounting change for goodwill

     (14,275 )     (3,744 )     (5,590 )     (8,652 )     (5,361 )     (4,246 )     (3,390 )     (3,145 )

Income (loss) from discontinued operations

     (48 )     62       (128 )     (156 )     (90 )     (358 )     —         —    

Cumulative effect of accounting change for goodwill

     (38,257 )     —         —         —         —         —         —         —    
    


 


 


 


 


 


 


 


Net loss

   $ (52,580 )   $ (3,682 )   $ (5,718 )   $ (8,808 )   $ (5,451 )   $ (4,604 )   $ (3,390 )   $ (3,145 )
    


 


 


 


 


 


 


 


Net loss per common share—basic and diluted:

                                                                

From continuing operations before cumulative accounting change

   $ (3.69 )   $ (0.96 )   $ (1.41 )   $ (2.18 )   $ (1.37 )   $ (1.11 )   $ (0.90 )   $ (0.84 )

Income (loss) from discontinued operations

     (0.01 )     0.02       (0.03 )     (0.04 )     (0.02 )     (0.09 )     —         —    

Cumulative effect of accounting change

     (9.89 )     —         —         —         —         —         —         —    
    


 


 


 


 


 


 


 


Net loss per common share—basic and diluted

   $ (13.59 )   $ (0.94 )   $ (1.44 )   $ (2.22 )   $ (1.39 )   $ (1.20 )   $ (0.90 )   $ (0.84 )
    


 


 


 


 


 


 


 


Weighted average common shares outstanding-basic and diluted

     3,868       3,901       3,965       3,966       3,922       3,837       3,750       3,744  
    


 


 


 


 


 


 


 


 

We have a limited operating history upon which to evaluate our business and to predict revenues and plan operating expenses. We expect our quarterly operating results to vary significantly in the future due to a variety of factors, many of which are outside our control.

 

22


Liquidity and Capital Resources

 

We have primarily funded our operations through private placements of our preferred stock during 1998 and 1999 and our initial public offering, which closed in November 1999. As of December 31, 2003, we had total cash and investments of $19.3 million, which is comprised of cash and cash equivalents of $13.1 million, short-term investments of $2.3 million and long-term investments of $3.9 million.

 

Cash used in operating activities was $9.3 million and $10.0 million during the years ended December 31, 2003 and 2002, respectively. Cash used in operating activities was principally for the development of our software solutions, our sales and marketing efforts and administration.

 

Cash provided (used) by investing activities during the years ended December 31, 2003 and 2002 was $11.2 million and $(3.1) million, respectively. Cash used in investing activities has primarily been comprised of purchases of investments in US government obligations, commercial paper and corporate bonds, purchases of computer equipment and the capitalization of certain costs associated with the development of our hosted applications and with the development of research software systems. Cash was primarily provided from the maturity of investments.

 

Cash used by financing activities during the years ended December 31, 2003 and 2002 was $0.2 million and $0.8 million, respectively. During 2003 and 2002, we repurchased 156,924 and 56,453 shares of its common stock for $0.6 million and $0.4 million, respectively. During the years ended December 31, 2003 and 2002, we received approximately $40,000 and $149,000, respectively, in proceeds from exercises of stock options and warrants and from purchases under the employee stock purchase plan.

 

During September 2003, we negotiated a modification and extension of our revolving line of credit with an increased commitment amount of $3.5 million. The line, which has a balance of $2,312,833 at December 31, 2003, is due on January 3, 2006. Interest is payable monthly at the lender’s prime rate (4.0% at December 31, 2003). The loan commitment is collateralized with restricted investments in the amount of $3,889,000 at December 31, 2003. The funds are available for working capital uses and no other significant conditions are applicable.

 

During September 2003, we subleased approximately 30% of our Newtown Square, Pennsylvania office facility. The sublease will reduce our rent costs by approximately $1.5 million over the next 7.5 years.

 

Over the last 24 months we have incurred cumulative operating losses of $49.8 million and used $19.3 million of cash in operations. We have reduced our spending to an average of $2.4 million for net cash used in operating activities for each of the last ten quarters following our 2001 restructuring. Based on this spending level, adjusted for our anticipated additional capital needs, we believe that our existing cash and investments of $19.3 million at December 31, 2003 will be sufficient to satisfy our cash requirements for more than the next twelve months. However, lower than expected cash flows as a result of lower revenues or increased expenses could require us to raise additional capital in order to maintain our operations. There are significant uncertainties, based on recent economic conditions and our limited operating experience as a software and related services provider, as to whether debt or equity financing will be available if we are required to seek additional funds. Even if we are able to secure funds in the debt or equity markets, we may not be able to do so on terms that are favorable or acceptable to us. Any additional equity financing, if available, could result in substantial dilution to our existing stockholders.

 

If we are unable to raise additional capital to continue to support our operations, we might be required to scale back, delay or discontinue one or more of our product offerings, which could have a material adverse effect on our business. Reduction or discontinuation of any one of our business components or product offerings could result in additional charges, which would be reflected in the period of the reduction or discontinuation.

 

Off-Balance Sheet Arrangements

 

Other than the contractual obligations described in the table below, we have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

23


In the normal course of business, we enter into various commitments that may require funds to settle our contractual obligations in the future. As discussed above, we have a revolving line of credit used for working capital needs that is classified as a long-term obligation. We have no capital leases, purchase obligations or other long-term liabilities at December 31, 2003. We have several operating leases that primarily relate to the rental of office space. These leases have various termination dates as discussed more fully in Note 12 of our Consolidated Financial Statements. Contractual obligations at December 31, 2003 are as follows:

 

     Payments due by period

Contractual Obligations


   Total

  

Less than

1 year


  

1 – 3

years


  

3 – 5

years


  

More than

5 years


Long-Term Debt Obligations

   $ 2,312,833    $ —      $ 2,312,833    $ —      $ —  

Capital Lease Obligations

     —        —        —        —        —  

Operating Lease Obligations

     9,700,822      2,194,701      2,800,670      2,176,724      2,528,727

Purchase Obligations

     —        —        —        —        —  

Other Long-Term Liabilities Reflected on the Balance Sheet

     —        —        —        —        —  
    

  

  

  

  

Total

   $ 12,013,655    $ 2,194,701    $ 5,113,503    $ 2,176,724    $ 2,528,727
    

  

  

  

  

 

In September 2003, we renewed a partial guarantee of a $440,000 real estate loan to a co-founder secured with a certificate of deposit in the amount of $245,000. The loan bears interest at prime rate and becomes payable in full in September 2004. A payment by SciQuest would be necessary only if the co-founder defaulted on the loan and the liquidation of the real estate was insufficient to alleviate the full balance of the obligation. The transaction was approved unanimously by the Company’s Board of Directors, all of whom were disinterested with respect to this transaction

 

Related Party Transactions

 

In February 2002, we guaranteed an $80,000 loan for Mr. M. Scott Andrews, a member of the Board of Directors and co-founder. The loan bears interest at prime rate and becomes payable in full in February 2004. We have agreed to reimburse Mr. Andrews for interest paid on this loan. The transaction was approved by a majority of our disinterested directors. We reimbursed Mr. Andrews for interest payments totaling $3,768 and $2,842, respectively, for the years ended December 31, 2003 and 2002. Mr. Andrews repaid the entire loan in February 2004, and consequently we have been released from our guarantee on this loan arrangement.

 

The Sarbanes-Oxley Act of 2002 prohibits companies from extending credit or arranging for the extension of credit for any director or executive officer in the form of a personal loan. Credit arrangements that were in place prior to this act may be maintained, but not renewed. Accordingly, we are fully compliant with this act and did not renew our guarantee after the maturity of this loan.

 

New Accounting Pronouncements

 

In June 2002, the Financial Accounting Standards Board issued Statement of Financial Accounting Standard No. 146, “Accounting for Costs Associated with Exit or Disposal Activities,” (“SFAS No. 146”). SFAS No. 146 nullifies Emerging Issues Task Force Issue No. 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring),” (“EITF No. 94-3”). SFAS No. 146 requires that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred. This is in contrast to EITF 94-3, which required recognition of a liability upon an entity’s commitment to an exit plan. SFAS No. 146 concludes that a commitment, by itself, does not create a present obligation meeting the definition of a liability. This statement establishes fair value as the objective for initial measurement of the liability. The provisions of SFAS No. 146 are effective for exit or disposal activities that are initiated after December 31, 2002. The adoption of SFAS No. 146 did not have any material impact on our financial statements or results of operations.

 

        In November 2002, the Financial Accounting Standards Board issued Financial Accounting Series FASB Interpretation No. 45, “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others—an interpretation of FASB Statements No. 5, 57, and 107 and rescission of FASB Interpretation No. 34” (“FIN No. 45”). FIN No. 45 elaborates on the disclosures to be made by a guarantor in its interim and annual financial statements regarding its obligations under certain guarantees that it has issued. It also clarifies that a guarantor is required to recognize, at the inception of a guarantee, a liability for the fair value of the obligation undertaken in issuing the guarantee. The initial recognition and initial measurement provisions of FIN No. 45 are applicable on a prospective basis to guarantees issued or modified after December 31, 2002, irrespective of the guarantor’s fiscal year-end. The disclosure requirements are effective for financial statements of interim or annual periods ending after December 15, 2002. The interpretive guidance incorporated without change from Interpretation 34 continues to be required for financial statements for fiscal years ending after June 15, 1981—the effective date of Interpretation 34. The adoption of FIN No. 45 did not have any impact on our financial statements or results of operations. The required disclosures as of December 31, 2003 are presented in Note 15 of the Consolidated Financial Statements.

 

        In December 2002, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 148, “Accounting for Stock-Based Compensation—Transition and Disclosure—an amendment of FASB Statement No. 123” (“SFAS No. 148”) which amends FASB Statement No. 123, “Accounting for Stock-Based Compensation,” to provide alternative methods of transition for an entity that voluntarily changes to the fair value based method of accounting for stock-based employee compensation. It also amends the disclosure provisions of that Statement to require prominent disclosure about the effects on reported net income of an entity’s accounting policy decisions with respect to stock-based employee compensation. SFAS No. 148 amends Accounting Principles

 

24


Board Opinion No. 28, “Interim Financial Reporting,” to require prominent disclosure in interim financial information. The provisions of SFAS No. 148 are effective for financial statements for fiscal years ending after December 15, 2002 with the interim reporting provisions effective for reporting periods beginning after December 15, 2002. The adoption of SFAS No. 148 did not have any material impact on our financial statements or results of operations since we continue to utilize the provisions of Accounting Principles Board Opinion No. 25 “Accounting for Stock Issued to Employees,” rather than voluntarily change to the fair value based method. The required disclosures as of December 31, 2003 are presented in Note 2 of the Consolidated Financial Statements.

 

In April 2003, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 149 “Amendment of Statement 133 on Derivative Instruments and Hedging Activities” (“SFAS No. 149”). FASB Statements No. 133 “Accounting for Derivative Instruments and Hedging Activities” and No. 138, “Accounting for Certain Derivative Instruments and Certain Hedging Activities”, establish accounting and reporting standards for derivative instruments including derivatives embedded in other contracts (collectively referred to as derivatives) and for hedging activities. SFAS No. 149 amends Statement 133 for certain decisions made by the Board as part of the Derivatives Implementation Group (DIG) process. This Statement contains amendments relating to FASB Concepts Statement No. 7, “Using Cash Flow Information and Present Value in Accounting Measurements”, and FASB Statements No. 65, “Accounting for Certain Mortgage Banking Activities”, No. 91 “Accounting for Nonrefundable Fees and Costs Associated with Originating or Acquiring Loans and Initial Direct Costs of Leases”, No. 95, “Statement of Cash Flows”, and No. 126, “Exemption from Certain Required Disclosures about Financial Instruments for Certain Nonpublic Entities”. The provisions of SFAS No. 149 are effective for contracts entered into or modified after June 30, 2003. The adoption of SFAS No. 149 did not have any material impact on our financial statements or results of operations.

 

In January 2003, the Financial Accounting Standards Board issued Financial Accounting Series FASB Interpretation No. 46, “Consolidation of Variable Interest Entities, an Interpretation of ARB No. 51” (“FIN No. 46”). The primary objective of the Interpretation is to provide guidance on the identification of, and financial reporting for, entities over which control is achieved through means other than voting rights; such entities are known as variable-interest entities (VIEs). FIN No. 46 has far-reaching effects and applies immediately to new entities created after January 31, 2003, as well as applies to existing entities in which an enterprise obtains an interest after that date. The provisions of FIN No. 46 are effective at the end of the first interim or annual period ending after December 15, 2003, to variable-interest entities in which an enterprise holds a variable interest that it acquired before February 1, 2003. FIN No. 46 is the guidance that determines (1) whether consolidation is required under the “controlling financial interest” model of Accounting Research Bulletin No. 51, “Consolidated Financial statements”, or other existing authoritative guidance, or, alternatively, (2) whether the variable-interest model under FIN No. 46 should be used to account for existing and new entities. The adoption of FIN No. 46 did not have any material impact on our financial statements or results of operations.

 

In May 2003, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 150 “Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity” (“SFAS No. 150”). SFAS No. 150 establishes standards for classification and measurement in the statement of financial position of certain financial instruments with characteristics of both liabilities and equity. It requires classification of a financial instrument that is within its scope as a liability (or an asset in some circumstances) because that financial instrument embodies an obligation of the issuer. SFAS No. 150 is effective for financial instruments entered into or modified after May 31, 2003, and otherwise shall be effective on July 1, 2003. The adoption of SFAS No. 150 did not have any material impact on our financial statements or results of operations.

 

Factors That May Affect Future Results

 

Our future operating results may vary substantially from period to period based on a number of factors. The price of our common stock will fluctuate in the future, and an investor in our common stock is subject to a variety of risks, including but not limited to the specific risks identified below. Current and prospective investors are strongly urged to carefully consider the various cautionary statements and risks set forth below and elsewhere in this report.

 

Since we have a limited operating history with our evolving business model, forecasting future performance may be difficult.

 

Our business model has evolved considerably since our company’s inception. For instance, we launched our public e-commerce marketplace in April 1999. Beginning with our acquisition of EMAX in March 2000, we have increasingly focused our efforts on providing software products and services to enhance research operations for pharmaceutical, biotechnology and other research-based organizations. We discontinued our order processing services in 2001. In 2002, we acquired the business operations of Textco, Groton NeoChem and HigherMarkets, each of which added new products and/or target markets to our business model. In 2003, we refocused our expenditures to support our procurement and materials management platform and divested the Textco business unit and the products related to BioSupplyNet and Groton NeoChem. Accordingly, we have only a limited operating history on which to evaluate our evolving business model. As a result of our limited operating history and the evolving nature of our business model, we may be unable to accurately forecast our revenues. We incur expenses based predominantly on operating plans and estimates of future revenues. Revenues to be generated from newly developed and evolving activities will be particularly difficult to forecast accurately. Our expenses are to a large extent fixed. We may be unable to adjust our spending in a timely manner to compensate for any unexpected revenue shortfalls. Accordingly, a failure to meet our revenue projections will have an immediate and negative impact on profitability. Finally, we cannot be certain that our evolving business model will be successful, particularly in light of our limited operating history.

 

25


We have a history of losses and anticipate incurring losses in the future. We may not achieve profitability.

 

We incurred a net loss of $16.6 million for the year ended December 31, 2003. To date, we have not realized any profits, and as of December 31, 2003, we had an accumulated deficit of $293 million. We expect to incur substantial operating losses and continued negative cash flow from operations for the foreseeable future. In fact, we expect to continue generating losses through at least 2004. We may not be able to increase revenues sufficiently to achieve profitability.

 

Our future profitability and cash flows are dependent upon our ability to control expenses.

 

Our operating plan to achieve profitability is based upon estimates of our future expenses. For instance, we expect our development expenses in 2004 to be comparable to such expenses in 2003 while we expect our sales and market expenses to increase slightly in 2004 and our general and administrative expenses to decrease slightly in 2004. If our future expenses are greater than anticipated, our ability to achieve profitability when expected may be negatively impacted. In addition, greater than anticipated expenses may negatively impact our cash flows, which could cause us to expend our capital faster than anticipated. While we expect our existing capital to be sufficient for more than the next twelve months, lower than expected cash flows due to increased expenses could require us to raise additional capital or significantly reduce expenses in order to maintain our operations. There can be no assurance that we will be able to raise such funds on favorable terms, or at all. Also, a large percentage of our expenses are relatively fixed, which may make it difficult to reduce expenses significantly in the future.

 

Our future profitability and cash flows are also dependent upon our ability to achieve revenue growth.

 

Our operating plan to achieve profitability is based upon estimates of our revenues and assumes that we will achieve license fee and related revenues that substantially exceed historical levels. Our ability to achieve this projected revenue growth is largely dependent on the results of our sales efforts. We increased certain sales and marketing expenses in 2003 in an effort to increase our revenue generation. We cannot assure you that our sales force will be successful in achieving the sales levels required to achieve profitability. If our future revenues are less than anticipated, our ability to achieve profitability when expected may be negatively impacted. In addition, lower than anticipated revenues may negatively impact our cash flows, which could cause us to expend our capital faster than anticipated. While we expect our existing capital to be sufficient for more than the next twelve months, lower than expected cash flows as a result of lower revenues could require us to raise additional capital in order to maintain our operations. There can be no assurance that we will be able to raise such funds on favorable terms, or at all.

 

Sales to larger customers may result in long sales cycles and decrease our profit margins.

 

Sales to large enterprise buyers are an important element of our business strategy. As we sell sophisticated solutions to larger organizations, we expect the average time from initial contact to final approval to be significant. During this sales cycle, we may expend substantial funds and management resources without any corresponding revenue. If approval is delayed or does not occur, our financial condition and operating results for a particular period may be adversely affected. Approvals are subject to delays over which we have little or no control, including the following:

 

  potential customers’ internal approval processes;

 

  budgetary constraints for information technology spending;

 

  implementation of systems integration solutions;

 

  customers’ concerns about implementing a new strategy and method of doing business; and

 

  seasonal and other timing effects.

 

Sales to large accounts may result in lower profit margins than other sales as larger customers typically have greater leverage in negotiating the price and other terms of business relationships. We also incur costs associated with customization of certain products and services with a sale to a large account. If we do not generate sufficient revenues to offset any lower margins or these increased costs, our operating results may be materially and adversely affected. Also, the time between billing and receipt of revenues is often longer when dealing with larger accounts due to increased administrative overhead.

 

We have relied, and continue to rely, on a limited number of large customers for a significant portion of our revenues. Losing one or more of these customers may adversely affect our revenues.

 

We expect that for the foreseeable future we will generate a significant portion of our revenues from a limited number of large customers. During the year ended December 31, 2003, one customer accounted for 20% of our total revenues. These large transactions are often non-recurring, making it difficult to predict future transactions. The failure of one or more large transactions to occur in any given period may materially and adversely affect our revenues for that period. If we lose any of our large customers or if we are unable to add new large customers, our revenues will not increase as expected. In addition, our reputation and brand name would be harmed.

 

26


This customer concentration may also increase our accounts receivable credit risk from time to time. The failure by any large customer to make payments when due would negatively impact our cash flows.

 

We are investing significantly in developing and acquiring new product and service offerings with no guarantee of success.

 

Expanding our product and service offerings is an important component of our business strategy. As such, we are expending a significant amount of our resources in these development and acquisition efforts. Any new offerings that are not favorably received by prospective customers could damage our reputation or brand name. Expansion of our services will require us to devote a significant amount of time and money and may strain our management, financial and operating resources. We cannot assure you that our development or acquisition efforts will result in commercially viable products or services. In 2003, for instance, we sold the Textco business unit to its original owners and divested our interests in the BioSupplyNet and Groton NeoChem products. In addition, we may bear development and acquisition costs in current periods that do not generate revenues until future periods, if at all. To the extent that we incur expenses that do not result in increased current or future revenues, our earnings may be materially and adversely affected.

 

Unless a broad range of purchasers and suppliers of products adopt our products and services, we will not be successful.

 

Our success will require, among other things, that our solutions gain broad market acceptance by purchasers and suppliers of products. For example, purchasers may continue managing assets and purchasing products through their existing methods and may not adopt new technology solutions because of:

 

  their comfort with current purchasing and asset management procedures;

 

  the costs and resources required to adopt new business procedures;

 

  reductions in capital expenditures or information technology spending;

 

  security and privacy concerns; or

 

  general reticence about technology or the Internet.

 

If we do not successfully market the SciQuest brand, our business may suffer.

 

We believe that establishing, maintaining and enhancing the SciQuest brand is critical in expanding our customer base. Some of our competitors already have well-established brands. Promotion of our brand will depend largely on continuing our sales and marketing efforts and providing high-quality products and services to our enterprise customers. We increased certain sales and marketing expenses in 2003. We cannot assure you that these additional expenses will be successful in generating additional revenue. We also launched new marketing campaigns in the second half of 2002 and during 2003. We cannot be certain that our new marketing efforts will be successful in marketing the SciQuest brand. If we are unable to successfully promote our brand, or if we incur substantial expenses in attempting to do so, our revenues and earnings could be materially and adversely affected.

 

Our future revenue growth could be impaired if our investment in indirect sales channels for our products is unsuccessful.

 

We have invested significant time and resources in developing indirect sales channels for our products through relationships with companies such as SCT and Microsoft Solomon Great Plains. We cannot assure you that our indirect sales channels will be successful or that we will be able to develop additional indirect sales channels. If these sales channels do not result in significant amounts of sales, our ability to achieve our revenue projections may be impaired. As we develop additional indirect sales channels, we may experience conflicts with our direct sales force to the extent that these sales channels target the same customer bases. Successful management of these potential conflicts will be necessary in order to maximize our revenue growth.

 

If we are not able to successfully integrate our systems with the internal systems of our customers, our operating costs and relationships with our suppliers and buyers will be adversely affected.

 

A key component of our products and services is the efficiencies created for suppliers and buyers. In order to create these efficiencies, it will often be necessary that our solutions integrate with customers’ internal systems, such as inventory, customer service, technical service, ERP systems and financial systems. In addition, there is little uniformity in the systems used by our customers. If these systems are not successfully integrated, relationships with our customers will be adversely affected, which could have a material adverse effect on our financial condition and results of operations.

 

27


If we are unable to adapt our products and services to rapid technological change, our revenues and profits could be materially and adversely affected.

 

Rapid changes in technology, products and services, user profiles and operating standards occur frequently. These changes could render our proprietary technology and systems obsolete. We must continually improve the performance, features and reliability of our products and services, particularly in response to our competition.

 

Our success will depend, in part, on our ability to:

 

  enhance our existing products and services;

 

  develop new services and technologies that address the increasingly sophisticated and varied needs of our target markets; and

 

  respond to technological advances and emerging industry standards and practices on a cost-effective and timely basis.

 

We cannot be certain of our success in accomplishing the foregoing. If we are unable, for technical, legal, financial or other reasons, to adapt to changing market conditions or buyer requirements, our market share could be materially and adversely affected.

 

Product development delays could damage our reputation and sales efforts.

 

Developing new products and updated versions of our existing products for release at regular intervals is important to our business efforts. At times, we may experience delays in our development process that result in new releases being delayed or lacking expected features or functionality. New product or version releases that are delayed or do not meet expectations may result in customer dissatisfaction, which in turn could damage significantly our reputation and sales efforts.

 

The market for technology solutions is highly competitive, which makes achieving market share and profitability more difficult.

 

The market for technology solutions in the life sciences and higher education markets is new, rapidly evolving and intensely competitive. We experience competition from multiple sources, which makes it difficult for us to develop a comprehensive business strategy that addresses all of these competitive factors. Competition is likely to intensify as this market matures.

 

As competitive conditions intensify, competitors may:

 

  devote greater resources to marketing and promotional campaigns;

 

  devote substantially more resources to product development;

 

  secure exclusive arrangements with customers that impede our sales; and

 

  enter into strategic or commercial relationships with larger, more established and well-financed companies.

 

In addition, new technologies and the expansion of existing technologies may increase competitive pressures. As a result of increased competition, we may experience reduced operating margins, as well as loss of market share and brand recognition. We may not be able to compete successfully against current and future competitors. These competitive pressures could have a material adverse effect on our revenue growth and earnings.

 

Our future revenue growth may be adversely affected by a significant reduction in spending in the life sciences and higher education markets.

 

We derive a significant portion of our revenue from the life sciences and higher education markets, primarily through fees for our software products and services. We expect our future growth to depend on spending levels in these markets. In addition, many companies have reduced spending on information technology products in response to current economic conditions. Any significant reduction in spending in the life sciences and higher education markets may have a material adverse effect on our revenues.

 

Our computer and telecommunications systems are in a single location, which makes them more vulnerable to damage or interruption.

 

Substantially all of our computer and telecommunications systems are located in the same geographic area. These systems are vulnerable to damage or interruption from fire, flood, power loss, telecommunications failure, break-ins and similar events. While we have business interruption insurance, this coverage may not adequately compensate us for lost business. Although we have implemented network security measures, our systems, like all systems, are vulnerable to computer viruses, physical or electronic break-ins and similar disruptions. These disruptions could lead to interruptions, delays and loss of data with respect to our hosted products. Any of these occurrences could have a material adverse effect on our revenues.

 

28


If we are unable to protect our intellectual property rights, our business could be materially and adversely affected.

 

Any misappropriation of our technology or the development of competing technology could seriously harm our business. We regard a substantial portion of our software products as proprietary and rely on a combination of copyright, trademark and trade secrets, customer license agreements and employee and third-party confidentiality agreements to protect our proprietary rights. These protections may not be adequate, and we cannot assure you that they will prevent misappropriation of our intellectual property, particularly in foreign countries where the laws may not protect proprietary rights as fully as do the laws of the United States. Other companies could independently develop similar or competing technology without violating our proprietary rights. The process of enforcing our intellectual property rights through legal proceedings would likely be burdensome and expensive, and our ultimate success could involve a high degree of risk.

 

Our products, trademarks and other proprietary rights may infringe on the proprietary rights of third parties, which may expose us to litigation.

 

While we believe that our products, trademarks and other proprietary rights do not infringe upon the proprietary rights of third parties, we cannot guarantee that third parties will not assert infringement claims against us in the future, particularly with respect to technology that we acquire through acquisitions of other companies. Any such claims could require us to enter into a license agreement or royalty agreement with the party asserting a claim. Even the successful defense of an infringement claim could result in substantial costs and diversion of our management’s efforts.

 

We are dependent on proprietary content and technology licensed from third parties, the loss of which could be costly.

 

We license a portion of the content and proprietary technology for our products and services from third parties. These third-party licenses may not be available to us on favorable terms, or at all, in the future. In addition, we must be able to successfully integrate this content and proprietary technology in a timely and cost-effective manner to create an effective finished product. If we fail to obtain the necessary third-party licenses on favorable terms or are unable to successfully integrate this content and proprietary technology on favorable terms, it could have a material adverse effect on our business operations.

 

Product defects or software errors in our products could adversely affect our business due to costly redesigns, production delays and customer dissatisfaction.

 

Design defects or software errors in our products may cause delays to product introductions or reduce customer satisfaction, either of which could materially and adversely affect our product sales and revenues. Our software products are highly complex and may contain design defects or software errors from time to time that may be difficult to detect or correct. In addition, our products are often critical to our customers’ business operations, which may magnify the impact of any design defects or software errors. Although we have license agreements with our customers that contain provisions designed to limit our exposure to potential claims and liabilities arising from customers, these provisions may not effectively protect us against all claims. In addition, claims arising from customer dissatisfaction could significantly damage our reputation and sales efforts.

 

If we fail to attract and retain key employees, our business may suffer.

 

A key factor of our success will be the continued services and performance of our executive officers and other key personnel. If we lose the services of any of our executive officers, our financial condition and results of operations could be materially and adversely affected. We do not have long-term employment agreements with any of our key personnel. Our success also depends upon our ability to identify, hire and retain other highly skilled technical, managerial, editorial, sales, marketing and customer service professionals. Competition for such personnel is intense. We cannot be certain of our ability to identify, hire and retain adequately qualified personnel. For example, we may encounter difficulties in attracting a sufficient number of qualified software developers. Failure to identify, hire and retain necessary technical, managerial, editorial, merchandising, sales, marketing and customer service personnel could have a material adverse effect on our financial condition and results of operations.

 

Many of our key executives and other employees have been employed by us for two years or less. If our employees do not work well together or some of our employees do not succeed in their designated roles, our financial condition and results of operations could be materially and adversely affected. We cannot be certain that our management, operational and financial resources will be adequate to support our future operations.

 

The failure to integrate successfully businesses that we have acquired or may acquire could adversely affect our business.

 

We have acquired and intend to continue seeking opportunities to acquire complementary businesses. For example, we acquired EMAX in 2000, and HigherMarkets in 2002. An element of our strategy is to broaden the scope and content of our products and services through the acquisition of existing products, technologies, services and businesses. Acquisitions entail numerous risks, including:

 

  the integration of new operations, products, services and personnel;

 

29


  the diversion of resources from our existing businesses, sites and technologies;

 

  the inability to generate revenues from new products and services sufficient to offset associated acquisition costs;

 

  the maintenance of uniform standards, controls, procedures and policies;

 

  accounting effects that may adversely affect our financial results;

 

  the impairment of employee and customer relations as a result of any integration of new management personnel;

 

  dilution to existing stockholders from the issuance of equity securities; and

 

  liabilities or other problems associated with an acquired business.

 

We may have difficulty in effectively assimilating and integrating these businesses, or any future joint ventures, acquisitions or alliances, into our operations. Any difficulties in the process could disrupt our ongoing business, distract our management and employees, increase our expenses and otherwise adversely affect our business. Any problems we encounter in connection with our acquisitions could have a material adverse effect on our business.

 

Our planned growth from international customers will require financial resources and management attention and could have a negative effect on our earnings.

 

We are investing resources and capital to expand our sales internationally, particularly in Europe. This will require financial resources and management attention and could have a negative effect on our earnings. We cannot be assured that we will be successful in creating international demand for our solutions and services. In addition, our international business may be subject to a variety of risks, including, among other things, increased costs associated with maintaining international marketing efforts, applicable government regulation, fluctuations in foreign currency, difficulties in collecting international accounts receivable and the enforcement of intellectual property rights. We cannot assure you that these factors will not have an adverse effect on future international sales and earnings. In addition, we are currently contemplating registering our trademarks in other countries. We cannot be assured that we will be able to do so.

 

Significant fluctuation in the market price of our common stock could result in securities class action claims against us.

 

Significant price and value fluctuations have occurred with respect to the securities of technology companies. Our common stock price has been volatile and is likely to be volatile in the future. In the past, following periods of downward volatility in the market price of a company’s securities, class action litigation has often been pursued against such companies. If similar litigation were pursued against us, it could result in substantial costs and a diversion of our management’s attention and resources.

 

New accounting rules could be proposed that could adversely affect our reported financial results.

 

Our financial statements are prepared based on generally accepted accounting principles and SEC accounting rules. These principles and rules are subject to change from time to time for various reasons. While we believe we meet all current financial reporting requirements, we cannot predict at this time whether any initiatives will be proposed or adopted that would require us to change our accounting policies. Any change to generally accepted accounting principles or SEC rules could adversely affect our reported financial results.

 

Items 7a: Quantitative and Qualitative Disclosures About Market Risk

 

Most of our cash equivalents, short-term and long-term investments and capital lease obligations are at fixed interest rates, therefore the fair value of these investments is affected by changes in market interest rates. However, because our investment portfolio is primarily comprised of investments in U.S. Government obligations and high-grade commercial paper, an immediate 10% change in market interest rates would not have a material effect on the fair market value of our portfolio. Therefore, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our investment portfolio.

 

Item 8. Financial Statements and Supplementary Data

 

The financial statements of SciQuest are filed together with this Report. See the Index to Consolidated Financial Statements on page F-1 for a list of the financial statements filed herewith.

 

30


Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None.

 

Item 9A. Controls and Procedures

 

Our Chief Executive Officer and our Controller, who serves as our principal financial officer, have reviewed the effectiveness our company’s disclosure controls and procedures as of December 31, 2003 (the “Evaluation Date”). Based on this review, these officers believe that such disclosure controls and procedures as of the Evaluation Date were adequate to ensure that material information relating to our company, including its consolidated subsidiaries, is made known to management by others within the company and its consolidated subsidiaries. To these officers’ knowledge, there were no significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the Evaluation Date.

 

31


PART III

 

Item 10. Directors and Executive Officers of the Registrant

 

Information concerning our executive officers can be found in Part I, Item 1, of this Form 10-K under the caption “Executive Officers” in accordance with Instruction 3 of Item 401(b) of Regulation S-K and General Instruction G(3) of Form 10-K. Information regarding our directors is presented under the caption “Election of Directors” in our definitive proxy statement for the annual meeting of stockholders to be held on June 16, 2004, which will be filed with the Securities and Exchange Commission on or about April 29, 2004, and is incorporated herein by reference.

 

Item 11. Executive Compensation

 

Information in answer to Item 11 is presented under the caption “Compensation of Executive Officers and Other Information” excluding the information under the captions “Report of the Officer Compensation Committee on Executive Compensation” and “Stockholder Return Performance Graph” in our definitive proxy statement for the annual meeting of stockholders to be held on June 16, 2004, which will be filed with the Securities and Exchange Commission on or about April 29, 2004, and is incorporated herein by reference.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management

 

Information in answer to Item 12 is presented under the caption “Stock Ownership” in our definitive proxy statement for the annual meeting of stockholders to be held on June 16, 2004, which will be filed with the Securities and Exchange Commission on or about April 29, 2004, and is incorporated herein by reference.

 

Item 13. Certain Relationships and Related Transactions

 

Information in answer to Item 13 is presented in Part I, Item 7 of this Form 10-K under the caption “Related Party Transactions” in accordance with Instruction 3 of Item 401(b) of Regulation S-K and General Instruction G(3) of Form 10-K. Information is also presented under the caption “Related Party Transactions” in our definitive proxy statement for the annual meeting of stockholders to be held on June 16, 2004, which will be filed with the Securities and Exchange Commission on or about April 29, 2004, and is incorporated herein by reference.

 

Item 14. Principal Accountant Fees and Services

 

Information in answer to Item 14 is presented under the caption “Ratification of Selection of Independent Auditors” in our definitive proxy statement for the annual meeting of stockholders to be held on June 16, 2004, which will be filed with the Securities and Exchange Commission on or about April 29, 2004, and is incorporated herein by reference.

 

32


PART IV

 

Item 15. Exhibits, Financial Statement Schedules and Reports on Form 8-K.

 

(a)     1. Financial Statements.

 

See the Index to Consolidated Financial Statements on page F-1 for a list of the financial statements filed herewith.

 

2. Financial Statement Schedules.

 

Not applicable.

 

3. List of Exhibits.

 

Exhibit

Number


 

Description


  3.1*   Second Amended and Restated Certificate of Incorporation of SciQuest.
  3.2*******   Amendment to Second Amended and Restated Certificate of Incorporation of SciQuest.
  3.3********   Amendment No. 2 to Second Amended and Restated Certificate of Incorporation of SciQuest.
  3.4*   Amended and Restated Bylaws of SciQuest.
  4.1*   See Exhibits 3.1 and 3.2 for provisions of the Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws of SciQuest defining rights of the holders of Common Stock of SciQuest.
  4.2*********   Specimen Stock Certificate.
10.1*   SciQuest Stock Option Plan dated as of September 4, 1997.
10.2*   Amendment No. 1 to SciQuest Stock Option Plan dated as of September 11, 1998.
10.3*   Amendment No. 2 to SciQuest Stock Option Plan dated as of February 26, 1999.
10.4*   Amendment No. 3 to SciQuest Stock Option Plan dated as of March 1, 1999.
10.5*   Amendment No. 4 to SciQuest Stock Option Plan dated as of August 27, 1999.
10.6*   Amendment No. 5 to SciQuest Stock Option Plan.
10.7*   SciQuest 1999 Stock Incentive Plan dated as of October 12, 1999.
10.8**   First Amendment to 1999 Stock Incentive Plan.
10.9**   Agreement and Plan of Merger and Reorganization between SciQuest, ESP Acquisition, Inc. and EMAX Solution Partners, Inc. dated March 13, 2000.
10.10**   SciQuest 2000 Employee Stock Purchase Plan.
10.11***   Second Amendment to 1999 Stock Incentive Plan.
10.12****   Form of Services Agreement.
10.13*****   Form of Master License and Services Agreement.
10.14*****  

Executive Employment Agreement by and between SciQuest and Stephen J. Wiehe,

dated February 5, 2002.

10.15******   Agreement and Plan of Merger, dated as of June 25, 2002, by and among SciQuest, HigherMarkets Acquisition, Inc. and HigherMarkets, Inc.

 

33


Exhibit

Number


 

Description


10.16*  

Lease Agreement by and between Duke-Weeks Realty Limited Partnership and SciQuest dated as

of October 19, 1999.

10.17*******  

Lease Agreement by and between Brandywine Operating Partnership, L.P. and SciQuest dated as

of October 2000.

10.18   Change of Control Agreement by and between Stephen J. Wiehe and SciQuest dated as of January 1, 2004.
10.19   Change of Control Agreement by and between James B. Duke and SciQuest dated as of January 1, 2004.
10.20   Change of Control Agreement by and between Kerry S. May and SciQuest dated as of January 1, 2004.
10.21   Change of Control Agreement by and between Suzanne Miglucci and SciQuest dated as of January 1, 2004.
14.1   Code of Ethics
21.1   Subsidiaries of SciQuest.
23.1   Consent of Independent Accountants.
31.1   Certificate of Chief Executive Officer
31.2   Certificate of Principal Financial Officer
32.1   Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

*

   Incorporated by reference to SciQuest’s Registration Statement on Form S-1 (Reg. No. 333-87433).

**

   Incorporated by reference to SciQuest’s Registration Statement on Form S-1 (Reg. No. 333-32582).

***

   Incorporated by reference to SciQuest’s Annual Report on Form 10-K for the year ended December 31, 2000.

****

   Incorporated by reference to SciQuest’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2001.

*****

   Incorporated by reference to SciQuest’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2002.

******

   Incorporated by reference to SciQuest’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2002.

*******

   Incorporated by reference to SciQuest’s Annual Report on Form 10-K for the year ended December 31, 2002.

********

   Incorporated by reference to SciQuest’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2003.

*********

   Incorporated by reference to SciQuest’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2003.

 

(b) Reports on Form 8-K

 

A current report on Form 8-K was filed on October 30, 2003, in connection with the release of SciQuest’s earnings for the quarter ended September 30, 2003.

 

34


Item 8—Financial Statements

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

     Page

SciQuest, Inc.:

    

Report of Independent Accountants

   F-2

Consolidated Balance Sheets as of December 31, 2002 and 2003

   F-3

Consolidated Statements of Operations for the Years Ended December 31, 2001, 2002 and 2003

   F-4

Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2001, 2002 and 2003

   F-5

Consolidated Statements of Cash Flows for the Years Ended December 31, 2001, 2002 and 2003

   F-8

Notes to Consolidated Financial Statements

   F-9

 

F-1


REPORT OF INDEPENDENT AUDITORS

 

To the Board of Directors and Stockholders of SciQuest, Inc.

 

In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations, of stockholders’ equity and of cash flows present fairly, in all material respects, the financial position of SciQuest, Inc. and its subsidiaries (the “Company”) at December 31, 2003 and 2002, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2003 in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Company’s management; our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with auditing standards generally accepted in the United States of America, which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

As discussed in Note 7 to the consolidated financial statements, the Company changed its method of accounting for goodwill upon the adoption of Statement of Financial Accounting Standards No. 142 on January 1, 2002.

 

/S/ PRICEWATERHOUSECOOPERS LLP

 

March 10, 2004

Raleigh, North Carolina

 

F-2


SciQuest, Inc.

 

CONSOLIDATED BALANCE SHEETS

 

     December 31,
2002


    December 31,
2003


 
Assets                 

Current assets:

                

Cash and cash equivalents

   $ 11,460,153     $ 13,128,169  

Short-term investments

     10,441,258       2,257,784  

Accounts receivable, net

     2,293,902       1,172,263  

Prepaid expenses and other current assets

     2,837,131       2,907,267  
    


 


Total current assets

     27,032,444       19,465,483  
    


 


Long-term investments

     9,254,841       3,889,000  

Property and equipment, net

     2,734,113       1,403,496  

Capitalized software and web site development costs, net

     8,192,335       5,940,667  

Other intangible assets, net

     415,642       182,843  

Other long-term assets

     209,961       999,953  
    


 


Total assets

   $ 47,839,336     $ 31,881,442  
    


 


Liabilities and Stockholders’ Equity                 

Current liabilities:

                

Accounts payable

   $ 406,830     $ 552,621  

Accrued liabilities

     5,680,935       5,624,956  

Deferred revenue

     2,621,444       3,765,603  

Current maturities of long-term debt and capital lease obligations

     44,721       —    
    


 


Total current liabilities

     8,753,930       9,943,180  
    


 


Long-term debt and capital lease obligations, less current maturities

     1,862,833       2,312,833  
    


 


Commitments and contingencies (Notes 12 and 13)

                

Stockholders’ equity:

                

Common stock, $0.001 par value; 90,000,000 shares authorized; 4,116,629 and 4,000,730 shares issued as of December 31, 2002 and 2003, respectively

     30,875       4,001  

Additional paid-in capital

     314,554,477       314,076,696  

Deferred compensation

     (101,549 )     —    

Deferred customer acquisition costs

     (5,208 )     —    

Accumulated other comprehensive loss

     (9,405 )     —    

Treasury stock, at cost; 96,987 and 253,911 shares as of December 31, 2002 and 2003, respectively

     (640,573 )     (1,258,948 )

Accumulated deficit

     (276,606,044 )     (293,196,320 )
    


 


Total stockholders’ equity

     37,222,573       19,625,429  
    


 


Total liabilities and stockholders’ equity

   $ 47,839,336     $ 31,881,442  
    


 


 

The accompanying notes are an integral part of these financial statements.

 

F-3


SciQuest, Inc.

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

     Year Ended December 31,

 
     2001

    2002

    2003

 

Revenues:

                        

License fees and other professional services

   $ 6,981,255     $ 6,520,953     $ 6,633,596  

E-commerce

     16,284,408       —         —    

Non-cash e-commerce incentive warrants benefit (expense)

     (54,236 )     —         —    
    


 


 


Total revenues

     23,211,427       6,520,953       6,633,596  
    


 


 


Cost of revenues:

                        

Cost of license fees and other professional services

     2,461,519       2,785,177       2,462,956  

Cost of license fees-amortization of acquired and capitalized software costs

     2,654,754       4,457,879       3,022,463  

Cost of e-commerce

     15,392,770       —         —    
    


 


 


Total cost of revenues

     20,509,043       7,243,056       5,485,419  
    


 


 


Gross profit (loss)

     2,702,384       (722,103 )     1,148,177  
    


 


 


Operating expenses:

                        

Development

     10,939,826       7,425,688       4,815,846  

Non-cash stock-based compensation

     350,694       279,711       63,531  
    


 


 


Total development expenses

     11,290,520       7,705,399       4,879,377  
    


 


 


Sales and marketing

     9,231,357       4,663,541       4,391,882  

Non-cash stock-based employee compensation and customer acquisition

     2,260,896       (332,560 )     6,134  
    


 


 


Total sales and marketing expenses

     11,492,253       4,330,981       4,398,016  
    


 


 


General and administrative

     14,650,615       8,472,131       7,070,865  

Non-cash stock-based employee compensation and amortization of intangibles

     40,149,687       1,921,390       88,863  
    


 


 


Total general and administrative expenses

     54,800,302       10,393,521       7,159,728  
    


 


 


Restructuring

     10,650,000       2,900,000       1,282,000  

Impairment of intangible assets

     —         7,155,914       —    
    


 


 


Total operating expenses

     88,233,075       32,485,815       17,719,121  
    


 


 


Operating loss

     (85,530,691 )     (33,207,918 )     (16,570,944 )
    


 


 


Other income (expense):

                        

Interest income

     3,032,563       1,068,799       504,837  

Interest expense

     (300,547 )     (116,518 )     (84,446 )

Other income (expense), net

     (38,430 )     (5,112 )     8,454  
    


 


 


Total other income, net

     2,693,586       947,169       428,845  
    


 


 


Loss from continuing operations before cumulative effect of accounting change for impairment of goodwill

     (82,837,105 )     (32,260,749 )     (16,142,099 )

Loss from discontinued operations (including loss on disposal of $247,417 on May 31, 2003)

     —         (269,541 )     (448,177 )

Cumulative effect of accounting change for impairment of goodwill

     —         (38,257,357 )     —    
    


 


 


Net loss

   $ (82,837,105 )   $ (70,787,647 )   $ (16,590,276 )
    


 


 


Net loss per common share—basic and diluted:

                        

From continuing operations before cumulative effect of accounting change

   $ (21.48 )   $ (8.22 )   $ (4.23 )

Loss from discontinued operations (including $0.06 from loss on disposal on May 31, 2003)

     —         (0.07 )     (0.12 )

Cumulative effect of accounting change

     —         (9.74 )     —    
    


 


 


Net loss per share-basic and diluted

   $ (21.48 )   $ (18.03 )   $ (4.35 )
    


 


 


Weighted average common shares outstanding—basic and diluted

     3,855,804       3,925,509       3,812,726  

 

The accompanying notes are an integral part of these financial statements.

 

F-4


SciQuest, Inc.

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

 

     Common Stock

  

Additional Paid
In Capital


   

Deferred

Compensation


   

Deferred

Customer

Acquisition

Costs


   

Accumulated

Other

Comprehensive

Income

(Loss)


   

Common Stock

In Treasury


   

Accumulated

Deficit


   

Total

Stockholders’

Equity


 
     Shares

   Amount

           Shares

    Amount

     

Balance at December 31, 2000

   3,826,146    28,696    319,475,952     (4,543,903 )   (4,849,235 )   (5,369 )   —       —       (122,981,292 )   187,124,849  

Issuance of Employee Stock Purchase Plan shares

   16,630    124    169,267     —       —       —       —       —       —       169,391  

Deferred partner acquisition costs related to estimated future issuance of stock warrants

   —      —      2,025     —       —       —       —       —       —       2,025  

Deferred partner acquisition costs related to issuance of stock warrants

   —      —      52,210     —       —       —       —       —       —       52,210  

Adjust deferred partner acquisition costs to fair value

   —      —      1,104,496     —       (1,149,796 )   —       —       —       —       (45,300 )

Amortization of deferred partner acquisition costs

   —      —      —       —       1,900,125     —       —       —       —       1,900,125  

Amortization of deferred compensation

   —      —      —       1,076,052     —       —       —       —       —       1,076,052  

Forfeiture of stock options

   —      —      (2,909,242 )   2,909,242     —       —       —       —       —       —    

Stock purchased for treasury

   —      —      —       —       —       —       (40,533 )   (281,088 )   —       (281,088 )

Exercise of common stock options and warrants

   47,294    356    36,889     —       —       —       —       —       —       37,245  

Foreign currency translation adjustment

   —      —      —       —       —       (12,775 )   —       —       —       (12,775 )

Net loss

   —      —      —       —       —       —       —       —       (82,837,105 )   (82,837,105 )
    
  
  

 

 

 

 

 

 

 

Balance at December 31, 2001

   3,890,070    29,176    317,931,597     (558,609 )   (4,098,906 )   (18,144 )   (40,533 )   (281,088 )   (205,818,397 )   107,185,629  

 

(continued)

 

The accompanying notes are an integral part of these financial statements.

 

F-5


SciQuest, Inc.

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY —(Continued)

 

     Common Stock

  

Additional
Paid

in Capital


   

Deferred

Compensation


   

Deferred

Customer

Acquisition

Costs


   

Accumulated

Other

Comprehensive

Income

(Loss)


   

Common Stock

In Treasury


    

Accumulated

Deficit


    

Total

Stockholders’

Equity


 
     Shares

   Amount

           Shares

     Amount

       

Balance at December 31, 2001

   3,890,070      29,176      317,931,597       (558,609 )     (4,098,906 )     (18,144 )   (40,533 )      (281,088 )      (205,818,397 )      107,185,629  

Issuance of common stock in exchange for all outstanding shares of Textco, Inc

   65,060      488      449,640       —         —         —       —          —          —          450,128  

Issuance of common stock in exchange for all outstanding shares of HigherMarkets, Inc

   115,942      870      576,956       —         —         —       —          —          —          577,826  

Issuance of Employee Stock Purchase Plan shares

   20,113      151      117,520       —         —         —       —          —          —          117,671  

Adjust deferred partner acquisition costs to fair value

   —        —        (1,842,747 )     —         1,833,812       —       —          —          —          (8,935 )

Amortization of deferred partner acquisition costs

   —        —        —         —         (383,990 )     —       —          —          —          (383,990 )

Amortization of deferred compensation

   —        —        —         391,562       —         —       —          —          —          391,562  

Forfeiture of deferred partner acquisition warrants

   —        —        (2,643,876 )     —         2,643,876       —       —          —          —          —    

Forfeiture of stock options

   —        —        (65,498 )     65,498       —         —       —          —          —          —    

Stock purchased for treasury

   —        —        —         —         —         —       (56,454 )      (359,485 )      —          (359,485 )

Exercise of common stock options and warrants

   25,444      190      30,885       —         —         —       —          —          —          31,075  

Foreign currency translation adjustment

   —        —        —         —         —         8,739     —          —          —          8,739  

Net loss

   —        —        —         —         —         —       —          —          (70,787,647 )      (70,787,647 )
    
  

  


 


 


 


 

  


  


  


Balance at December 31, 2002

   4,116,629    $ 30,875    $ 314,554,477     $ (101,549 )   $ (5,208 )   $ (9,405 )   (96,987 )    $ (640,573 )    $ (276,606,044 )    $ 37,222,573  

 

(continued)

 

The accompanying notes are an integral part of these financial statements.

 

F-6


SciQuest, Inc.

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY —(Continued)

 

    Common Stock

   

Additional

Paid

in Capital


   

Deferred

Compensation


   

Deferred

Customer

Acquisition

Costs


   

Accumulated

Other

Comprehensive

Income

(Loss)


    Common Stock In
Treasury


   

Accumulated

Deficit


   

Total

Stockholders’

Equity


 
    Shares

    Amount

            Shares

    Amount

     

Balance at December 31, 2002

  4,116,629       30,875       314,554,477       (101,549 )     (5,208 )     (9,405 )   (96,987 )     (640,573 )     (276,606,044 )     37,222,573  

Adjustment of common stock given in exchange for all outstanding shares of HigherMarkets, Inc

  (28,986 )     (217 )     (97,609 )     —         —         —       —         —         —         (97,826 )

Receipt and retirement of common stock in exchange for all assets of the BioSupplyNet Sourcebook

  (35,875 )     (36 )     (157,455 )     —         —         —       —         —         —         (157,491 )

Receipt and retirement of common stock in exchange for all outstanding shares of Textco, Inc.

  (65,060 )     (65 )     (266,942 )     —         —         —       —         —         —         (267,007 )

Issuance of Employee Stock Purchase Plan shares

  12,705       47       39,686       —         —         —       —         —         —         39,733  

Effect of reverse stock split

  (298 )     (26,613 )     25,273       —         —         —       —         —         —         (1,340 )

Adjust deferred partner acquisition costs to fair value

  —         —         1,311       —         (1,311 )     —       —         —         —         —    

Amortization of deferred partner acquisition costs

  —         —         —         —         6,519       —       —         —         —         6,519  

Amortization of deferred compensation

  —         —         —         78,869       —         —       —         —         —         78,869  

Forfeiture of stock options

  —         —         (22,680 )     22,680       —         —       —         —         —         —    

Stock purchased for treasury

  —         —         —         —         —         —       (156,924 )     (618,375 )     —         (618,375 )

Exercise of common stock options and warrants

  1,615       10       635       —         —         —       —         —         —         645  

Foreign currency translation adjustment

  —         —         —         —         —         9,405     —         —         —         9,405  

Net loss

  —         —         —         —         —         —       —         —         (16,590,276 )     (16,590,276 )
   

 


 


 


 


 


 

 


 


 


Balance at December 31, 2003

  4,000,730     $ 4,001     $ 314,076,696     $ —       $ —       $ —       (253,911 )   $ (1,258,948 )   $ (293,196,320 )   $ 19,625,429  
   

 


 


 


 


 


 

 


 


 


 

The accompanying notes are an integral part of these financial statements.

 

F-7


SciQuest, Inc.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

     Year Ended December 31,

 
     2001

    2002

    2003

 

Cash flows from operating activities

                        

Net loss

   $ (82,837,105 )   $ (70,787,647 )   $ (16,590,276 )

Adjustments to reconcile net loss to net cash used in operating activities:

                        

Depreciation and amortization

     48,779,403       10,105,189       5,189,882  

Bad debt expense

     560,426       225,000       50,000  

Non-cash buyer incentive warrants

     8,935       (8,935 )     —    

Loss on disposal from discontinued operations

     —         —         247,417  

Non-cash disposal of product lines

     —         —         (157,491 )

Accounting change-impairment of goodwill

     —         38,257,357       —    

Impairment of intangible assets

     —         7,155,914       —    

Amortization of deferred compensation

     1,076,052       391,562       78,869  

Amortization of deferred customer acquisition costs

     2,100,123       (383,990 )     6,519  

Amortization of discount on investments

     11,753       256,901       129,554  

Loss from disposal of fixed assets

     73,947       80,858       110,995  

Asset write downs and other charges of restructuring

     6,668,921       2,900,000       1,282,000  

Changes in operating assets and liabilities:

                        

Accounts receivable

     10,764,978       2,350,071       1,071,639  

Prepaid expenses and other current assets

     1,441,983       37,124       101,498  

Other assets

     2,963,508       348,489       (789,992 )

Accounts payable

     (5,806,626 )     123,246       145,791  

Accrued liabilities

     (2,496,696 )     (1,427,725 )     (1,358,174 )

Deferred revenue

     1,111,723       408,781       1,144,159  
    


 


 


Net cash used in operating activities

     (15,578,675 )     (9,967,805 )     (9,337,610 )
    


 


 


Cash flows from investing activities

                        

Purchase of property and equipment and capitalized software

     (7,348,292 )     (2,652,906 )     (2,273,525 )

Proceeds from sale of equipment

     147,833       129,750       24,043  

Cash received from acquisitions

     —         49,092       —    

Cash paid for acquisitions

     —         (1,038,188 )     —    

Maturity of investments

     52,781,738       34,064,959       19,650,649  

Purchase of investments, including restricted cash

     (24,361,004 )     (33,700,581 )     (6,230,888 )
    


 


 


Net cash provided by (used in) investing activities

     21,220,275       (3,147,874 )     11,170,279  
    


 


 


Cash flows from financing activities

                        

Borrowings under notes payable

     2,300,000       750,000       750,000  

Repayment of notes payable

     —         (1,187,167 )     (300,000 )

Repayment of capital lease obligations

     (2,647,259 )     (154,946 )     (44,721 )

Proceeds from exercise of common stock warrants and options

     37,245       31,075       645  

Proceeds from issuance of common stock under employee stock purchase plan

     169,391       117,671       39,733  

Shares repurchased and retired from reverse stock split

     —         —         (1,340 )

Purchase of treasury stock

     (281,088 )     (359,485 )     (618,375 )
    


 


 


Net cash used in financing activities

     (421,711 )     (802,852 )     (174,058 )
    


 


 


Effect of exchange rate changes on cash and cash equivalents

     (12,775 )     8,739       9,405  
    


 


 


Net increase (decrease) in cash and cash equivalents

     5,207,114       (13,909,792 )     1,668,016  

Cash and cash equivalents at beginning of period

     20,162,831       25,369,945       11,460,153  
    


 


 


Cash and cash equivalents at end of period

   $ 25,369,945     $ 11,460,153     $ 13,128,169  
    


 


 


 

The accompanying notes are an integral part of these financial statements.

 

F-8


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

1. The Company

 

Nature of Operations

 

SciQuest, Inc. (“SciQuest” or the “Company”), which began operations in 1995, provides on-demand supplier relationship management solutions that integrate organizations with their suppliers to enable comprehensive spend management. Spend management is the ability to view and analyze all spending across an enterprise, thereby providing greater insight into purchasing functions and giving an organization control and visibility to allow it to manage spending more effectively. SciQuest’s suite of modular applications helps companies to automate the spend management process. These solutions facilitate a company’s purchasing functions by reducing redundant tasks throughout the cycle of finding, acquiring and managing goods, which can result in increased efficiency, reduced cost and increased insight into an organization’s buying patterns. SciQuest targets the life sciences and higher education markets.

 

SciQuest generates revenues by charging license, subscription and maintenance fees for the use of its technology. SciQuest also offers professional services related to these solutions, for activities such as project implementation and training. In addition, SciQuest receives revenue from scientific supply manufacturers for converting their product catalogs into an electronic format, enhancing or enriching the data and distributing the information as directed by the suppliers. In addition, SciQuest has historically earned revenue for advertising on its web sites and advertising in the printed catalogue of scientific products (the “Source Book”). Source Book revenue has primarily been recognized in the second quarter of each fiscal year. During 2003, the Company divested its investment in the net assets related to BioSupplyNet (including the Source Book), Groton NeoChem and Textco, Inc. As a result, the Company does not anticipate earning significant future revenue from advertising related to web sites or printed catalogues.

 

Prior to 2002, the Company earned revenues from e-commerce transactions generated by purchases made through the SciQuest web sites. Effective May 1, 2001, the Company ceased taking title to products sold through its e-commerce solution. Therefore, there is no revenue from e-commerce transactions in 2002 and 2003.

 

Liquidity

 

The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company had an accumulated deficit of $293 million at December 31, 2003, and during the year then ended used cash in operating activities of $9.3 million and incurred a net loss of $16.6 million. The Company expects to continue generating losses through at least 2004.

 

The Company has funded its operations primarily through private placements of preferred stock during 1998 and 1999 and its 1999 initial public offering. As of December 31, 2003, the Company had total cash and investments of $19.3 million, which is comprised of cash and cash equivalents of $13.1 million, short-term investments of $2.3 million and long-term investments of $3.9 million.

 

During 2001, the Company restructured its operations and transitioned from an e-commerce transaction company to a software and related services provider. As a result, there is only limited operating history under the current business model with which to estimate future performance. The Company’s cash flow is dependent on its ability to control expenses and achieve revenue growth which is dependent on the Company’s ability to sell software licenses and related services as well as acquire or develop new products and service offerings. Additionally, 20% of the Company’s revenue for the year ended December 31, 2003 was generated by one customer, and the Company expects that large individual transactions with major customers may continue to represent a large percentage of revenues.

 

There are significant uncertainties, based on recent economic conditions and the Company’s limited operating experience as a software and related services provider, as to whether debt or equity financing will be available if the Company is required to seek additional funds. If the Company is able to secure funds in the debt or equity markets, it may not be able to do so on terms that are favorable or acceptable to the Company. Additional equity financing would likely result in substantial dilution to existing stockholders. If the Company is unable to raise additional capital to continue to support operations, it may be required to scale back, delay or discontinue one or more product offerings, which could have a material adverse effect on the Company’s business. Reduction or discontinuation of any one of the Company’s business components or product offerings could result in additional charges, which would be reflected in the period of the reduction or discontinuation.

 

Based on the average quarterly cash outlay for operating expenses incurred in the ten quarters after the June 2001 restructuring and budgeted expenditures for 2004, the Company believes cash and investments at December 31, 2003 will be sufficient to satisfy requirements for more than the next twelve months. However, lower than expected cash flows as a result of lower revenues or increased expenses could require the Company to raise additional capital in order to maintain its operations.

 

F-9


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

2. Summary of Significant Accounting Policies

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Principles of Consolidation

 

During the second quarter of 2003, the Company reorganized its corporate structure dissolving SciQuest Europe, Limited, and sold Textco, Inc., a wholly-owned subsidiary. As of December 31, 2003, the consolidated financial statements include the accounts of SciQuest, Inc. and its wholly-owned subsidiary, HigherMarkets, Inc. (“HigherMarkets”). All significant intercompany accounts and transactions have been eliminated. Prior to the reorganization and sale, the consolidated financial statements include the accounts of SciQuest, Inc. and its wholly-owned subsidiaries, SciQuest Europe, Limited (formerly EMAX Solution Partners (UK) Limited), Textco, Inc. (“Textco”) and HigherMarkets, Inc. All significant intercompany accounts and transactions have been eliminated.

 

As of December 31, 2001, the Company reorganized its corporate structure and dissolved Internet Auctioneers International, Inc., Intralogix, Inc., SciCentral, Inc., and merged BioSupplyNet, Inc. and EMAX Solution Partners, Inc. (“EMAX”) with SciQuest, Inc. As of December 31, 2002, the consolidated financial statements include the accounts of SciQuest, Inc. and its wholly-owned subsidiaries, SciQuest Europe, Limited (formerly EMAX Solution Partners (UK) Limited), Textco, Inc. and HigherMarkets, Inc. All significant intercompany accounts and transactions have been eliminated.

 

The consolidated financial statements prior to 2002 include the accounts of SciQuest, Inc. and its wholly-owned subsidiaries, BioSupplyNet, Inc., Internet Auctioneers International, Inc., Intralogix, Inc., SciCentral, Inc., EMAX Solution Partners, Inc., EMAX Solution Partners (UK) Limited and SciQuest Europe Limited. All significant intercompany accounts and transactions have been eliminated.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents.

 

Investments

 

The Company considers all investments that are not considered cash equivalents and with a maturity of less than one year from the balance sheet date to be short-term investments. The Company considers all investments with a maturity of greater than one year to be long-term investments. All investments are considered as held-to-maturity and are carried at amortized cost, as the Company has both the positive intent and ability to hold them to maturity. Interest income includes interest, amortization of investment purchase premiums and discounts, and realized gains and losses on sales of securities. Realized gains and losses on sales of investment securities are determined based on the specific identification method.

 

Restricted Cash

 

At December 31, 2003, restricted cash of $500,000, $245,000 and $3,889,000 included in cash and cash equivalents, short-term investments and long-term investments, respectively, is comprised of certificates of deposit, money market and other investment accounts which serve as collateral for the Company’s lease commitments, officer and founder loans guaranteed by the Company and long-term debt.

 

Accounts Receivable

 

The Company bears all risk of loss on credit sales including sales during prior years of scientific products in e-commerce transactions. Accounts receivable are presented net of an allowance for doubtful accounts of approximately $332,000 and $152,000 at

 

F-10


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

December 31, 2002 and 2003, respectively. Following is a schedule of the allowance for doubtful accounts for each year of the three years ended December 31, 2003:

 

     Years Ended December 31,

 
     2001

    2002

    2003

 
     (In Thousands)  

Allowance for doubtful accounts—Accounts receivables:

        

Balance, beginning of period

   $ 788     $ 1,124     $ 332  

Additions to allowance

     560       225       50  

Deductions, net of recoveries

     (224 )     (1,017 )     (230 )
    


 


 


Balance, end of period

   $ 1,124     $ 332     $ 152  
    


 


 


 

Property and Equipment

 

Property and equipment is primarily comprised of furniture and computer equipment which are recorded at cost and depreciated using the straight-line method over their estimated useful lives which are usually seven years for furniture and three to five years for computer software and equipment. Property and equipment includes certain equipment under capital leases. These items are depreciated over the shorter of the lease period or the estimated useful life of the equipment.

 

Expenses for repairs and maintenance are charged to operations as incurred. Upon retirement or sale, the cost of the disposed assets and the related accumulated depreciation are removed from the accounts, and any resulting gain or loss is credited or charged to operations.

 

Development Costs

 

Development costs include expenses incurred by the Company to develop, enhance, manage, monitor and operate the Company’s hosted software solutions, to manage and integrate data related to these solutions and to develop software to be licensed. The Company accounts for the software development component of internal use software development costs in accordance with Statement of Position No. 98-1 which requires certain costs associated with the development of the Company’s hosted solutions and internal applications to be capitalized and amortized to development expense over the useful life of the related applications. Capitalized development costs are amortized over the estimated life of the related application, which generally range from three months to two years.

 

Capitalized Software Costs

 

Software development costs related to software products sold to customers are required to be capitalized beginning when a product’s technological feasibility has been established and ending when a product is available for general release to customers. Capitalized software costs resulted from the acquisitions of EMAX, Textco, Groton NeoChem and HigherMarkets (see Note 3) as determined by valuations prepared by management and from developing standardized versions of software products for sale. Capitalized software costs are amortized over the period of expected benefit, which is typically two to four years, at a rate based on the higher of the straight-line or expected revenue methods.

 

Intangible Assets

 

Intangible assets consist of goodwill and certain other intangible assets acquired in the Company’s various acquisitions. Goodwill is recorded as an asset and tested for impairment annually on December 31. Prior to 2002, goodwill was amortized over a period of three to five years. All other intangible assets are amortized over the period the Company expects to benefit from their use, typically a period of two to three years.

 

The Company evaluates the recoverability of goodwill and other intangible assets according to the applicable accounting standards in order to determine whether impairments have occurred. For goodwill, an impairment is recognized whenever the carrying value of the goodwill and its related assets exceeds fair value, which is normally measured as the sum of the estimated future discounted cash flows attributable to the business component to which the asset relates (see Note 7).

 

Fair Value of Financial Instruments

 

        The carrying values of cash and cash equivalents, accounts payable and accounts receivable at December 31, 2002 and 2003 approximated their fair values due to the short-term nature of these items. The Company considers its short-term and long-term investments to be held-to-maturity, and therefore these investments are carried at amortized cost. The fair value of the Company’s short-term and long-term investments at December 31, 2002 and 2003, based on market quotes, is presented in Note 4.

 

F-11


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Impairment of Long-Lived Assets

 

The Company evaluates the recoverability of its property and equipment and intangible assets in accordance with Statement of Financial Accounting Standards No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets” (“SFAS No. 144”). SFAS No. 144 requires long-lived assets to be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment is recognized in the event that the net book value of an asset exceeds the future undiscounted cash flows attributable to such asset or the business to which such asset relates and the net book value exceeds fair value. The impairment amount is measured as the amount by which the carrying amount of a long-lived asset (or asset group) exceeds its fair value.

 

In March 2000, the Company acquired all of the outstanding common and preferred stock of EMAX and allocated $22,000,000 of the purchase price to trademarks. Subsequently, the value of the trademarks was being amortized to expense over a three-year period. During the first quarter of 2002, the Company discontinued utilizing the EMAX trademarks, and accordingly, determined that the carrying value of the trademarks had been impaired. As a result, the Company recognized a charge to income of $7,155,914, the unamortized balance at March 31, 2002, ($1.84 per share) in the first quarter of 2002. As part of the restructuring plans during the year ended December 31, 2001, an impairment of approximately $6.7 million, respectively, of long-lived assets were recognized related to the elimination of unprofitable business lines (see Notes 7 and 16).

 

The Company adopted Statement of Financial Accounting Standards No. 142, “Goodwill and other Intangible Assets” (“SFAS No. 142”) effective January 1, 2002. This statement addresses accounting and reporting for acquired goodwill and intangible assets. In accordance with the transitional provisions of SFAS No. 142, the Company determined that the carrying value of goodwill and related assets exceeded their fair value. As a result, the Company recognized a charge to income of $38,257,357 ($9.74 per share), as the cumulative effect of a change in accounting principle during the first quarter of 2002 (see Note 7).

 

Revenue Recognition

 

SciQuest generates revenues by charging license, subscription and maintenance fees for the use of its technology. SciQuest also offers professional services related to these solutions, for activities such as project implementation and training. In addition, SciQuest receives revenue from scientific supply manufacturers for converting their product catalogs into an electronic format, enhancing or enriching the data and distributing the information as directed by the suppliers. Until the third quarter of 2001, the Company earned much of its revenues from the sale of scientific products through its e-commerce web sites. The Company is no longer offering order-processing services and expects no substantial transaction revenues in the future.

 

The Company sells subscriptions to its hosted e-procurement solutions and materials management solutions. The implementation services and the total subscription fees are recognized ratably over the term of the agreement. Revenues from the sale of software licenses and custom development and implementation services under fixed-fee contracts are recognized using the percentage-of-completion method over the term of the development and implementation services. Revenues from the sale of standardized versions of software are recognized upon customer acceptance in accordance with Statement of Position 97-2, “Software Revenue Recognition.” Revenues from implementation services are recognized concurrently with the effort and costs incurred by the Company, at billable rates specified in the terms of the contract. Losses expected to be incurred on custom development and implementation services contracts in process, for which the fee is fixed, are charged to income in the period in which the estimated losses are initially identified. The Company sells maintenance contracts to provide updates and standard enhancements to its software products. Maintenance fee revenue is recognized ratably over the term of the arrangements, generally one year.

 

The Company also generates revenues by charging scientific supply manufacturers for data conversion and maintenance services. The related revenues for supplier data conversion and maintenance services are recognized ratably over the period of the agreements.

 

Advertising revenues are recognized ratably over the period in which the advertisement is displayed, provided that the Company has no significant remaining obligations to the advertiser and that collection of the resulting receivable is probable. Revenues from advertising included in the Source Book are recognized at the date the Source Book is published and distributed to the purchasers of scientific products as the Company has met all of its obligations to the advertisers at that date. Source Book revenue is included in license fees and other professional services and has historically been recognized in the second quarter of each fiscal year.

 

Prior to May 1, 2001, the Company took legal title to the products that were purchased from its suppliers and that, in turn, were sold to its customers in e-commerce transactions. Therefore, through April 2001, revenues received from the sale of scientific products in e-commerce

 

F-12


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

transactions and from the sale of scientific equipment were recorded as product revenues on a gross basis and were recognized by the Company upon delivery to the customer. As of May 1, 2001, the Company no longer took legal title to these products. Instead, the Company acted as an agent on behalf of the customer, and title passed directly from the supplier to the customer.

 

Since the Company acted as an agent for the customer and not as the primary obligor in the transaction for orders on or after May 1, 2001, the Company no longer recorded sales of scientific products and scientific equipment in e-commerce transactions on a gross basis. For each sale, the Company recognized revenue in the amount of the net commission that it earned for processing the transaction and/or payment for services. As a result of this change, much lower revenues from e-commerce transactions were recorded; however, the calculation of gross profit dollars from e-commerce transactions remained the same, although the gross margin as a percentage of related net revenue increased. As a result, the e-commerce revenues of $16,284,000 for the year ended December 31, 2001 relate to a total value of transactions processed of $25.7 million. During the second half of 2001, the Company phased out order processing services provided to customers, thereby eliminating e-commerce transaction volume for 2002 and 2003.

 

Cost of Revenues

 

The cost of software licensing, implementation and maintenance revenues consists primarily of personnel costs for employees who work directly on the development and implementation of customized electronic research solutions and who provide maintenance to customers, and also consists of the amortization of capitalized software development costs. The cost of revenue for subscriptions to e-procurement solutions and materials management solutions and for the related implementation services is recognized ratably over the term of the agreement. Cost of advertising revenue includes the cost of preparing the advertisements for display on the Company’s web sites and the cost of publishing and distributing the Source Book. Advertising production costs are recorded as cost of revenues the first time an advertisement appears on the Company’s web sites.

 

Cost of e-commerce revenues represents the purchase price to the Company of the scientific products sold through its e-commerce web sites and of scientific equipment, shipping and handling fees and the cost of maintaining such web sites. Prior to May 1, 2001, the Company generally took legal title to the scientific products and equipment purchased at the date of shipment and relinquished title to its customers upon delivery. Effective May 1, 2001, the Company stopped taking legal title to these products and recorded revenue on a net basis for the remainder of 2001. There have been no e-commerce transactions in 2002 and 2003.

 

Sales and Marketing Expenses

 

Sales and marketing expenses consist primarily of costs, including salaries and sales commissions, of all personnel involved in the sales process. Sales and marketing expenses also include costs of advertising, trade shows and certain indirect costs and amortization of deferred customer acquisition costs (see Note 14). All costs of advertising the services and products offered by the Company are expensed as incurred. Advertising expense totaled approximately $112,000, $5,000, and $23,000 for the years ended December 31, 2001, 2002 and 2003, respectively.

 

Deferred Customer Acquisition Costs and Incentive Warrants

 

Deferred customer acquisition costs relate to common stock warrants given in 1999 to several key suppliers and buyers of scientific products. The amount of deferred customer acquisition costs is and will be adjusted in each reporting period based on changes in the fair value of the underlying common stock until such date as the warrants are fully vested and non-forfeitable or cancelled. Deferred customer acquisition costs will be amortized as a non-cash charge to sales and marketing expense over the term of the related contractual relationship using a cumulative catch-up method (see Note 14). The terms of the contractual relationships range from three to five years.

 

In addition, in 1999 the Company agreed to issue to certain major enterprise buyers additional incentive warrants, the number of which will be based on each buyer’s volume of purchases during the years 2000, 2001 and 2002. The value of these warrants will be determined using the Black-Scholes Model at the issuance date, adjusted periodically using the cumulative catch-up approach. Deferred customer acquisition costs are presented net of accumulated amortization. As the Company discontinued the order processing services in May 2001, there will be no additional warrants earned subsequent to such date. During 2002, the incentive warrants were cancelled so there was no expense related to these warrants during the year ended December 31, 2003.

 

F-13


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Income Taxes

 

The Company accounts for income taxes using the liability method which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax bases of the Company’s assets and liabilities and for tax carryforwards at enacted statutory tax rates in effect for the years in which the differences are expected to reverse.

 

The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. In addition, valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

 

Stock Based Compensation

 

The Company accounts for non-cash stock based compensation in accordance with the provisions of Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” (“APB No. 25”), and its related interpretations, which states that no compensation expense is recognized for stock options or other stock-based awards to employees that are granted with an exercise price equal to or above the estimated fair value per share of the Company’s common stock on the grant date. In the event that stock options are granted with an exercise price below the estimated fair market value of the Company’s common stock at the grant date, the difference between the fair market value of the Company’s common stock and the exercise price of the stock option is recorded as deferred compensation. Deferred compensation is amortized to compensation expense over the vesting period of the related stock option. The Company recognized $1,076,052, $391,562 and $78,869 in non-cash compensation expense related to amortization of deferred compensation during the years ended December 31, 2001, 2002 and 2003, respectively. The plans are described more fully in Note 11.

 

The Company has adopted the disclosure requirements of Statement of Financial Accounting Standards No. 123, “Accounting for Stock-Based Compensation” (“SFAS No. 123”) as amended by Statement of Financial Accounting Standards No. 148, “Accounting for Stock-Based Compensation—Transition and Disclosure—an amendment of FASB Statement No. 123” which requires certain pro forma disclosures as if compensation expense was determined based on the fair value of the options granted at the date of the grant.

 

Had compensation expense for the plans been determined based on the fair value at the grant dates for awards under the plans consistent with the methods of SFAS No. 123, the Company’s net loss for the years ended December 31, 2001, 2002 and 2003 would have been increased to the pro forma amounts indicated below:

 

     2001

    2002

    2003

 

Net loss available to common stockholders:

                        

As reported

   $ (82,837,105 )   $ (70,787,647 )   $ (16,590,276 )

Add: Stock-based employee compensation expense included in reported net income, net of tax related effects

     1,076,052       391,562       78,869  

Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects

     (5,996,353 )     (4,313,640 )     (2,714,039 )
    


 


 


SFAS 123 proforma

   $ (87,757,406 )   $ (74,709,725 )   $ (19,225,446 )
    


 


 


Loss per share—basic and diluted:

                        

As reported

   $ (21.48 )   $ (18.03 )   $ (4.35 )
    


 


 


SFAS 123 proforma

   $ (22.76 )   $ (19.03 )   $ (5.04 )
    


 


 


 

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions used for grants during the years ended December 31, 2001, 2002 and 2003: risk free interest of 4.6%, 3.8% and 3.0%, respectively; expected lives of five years; dividend yields of 0%; and volatility factors of 139%, 128% and 116%, respectively. The weighted average fair value of options granted during the years ended December 31, 2001, 2002 and 2003 according to the Black-Scholes pricing model was $8.33, $7.28 and $3.15, respectively.

 

Credit Risk, Significant Customers and Concentrations

 

        Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, accounts receivable and investments. Cash and cash equivalents are deposited with high credit quality financial institutions which invest primarily in U.S. Government securities, highly rated commercial paper and certificates of deposit guaranteed by banks which are members of the FDIC. The counterparties to the agreements relating to the Company’s investments consist primarily of the U.S. Government and various major corporations with high credit standings.

 

F-14


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

During 2001, three customers comprised 12%, 13% and 21%, respectively, of the Company’s revenue with only the 12% customer being reportable in the segment for license fees and other professional services. During 2002, two customers comprised 20% and 13%, respectively, of the Company’s revenue. During 2003, one customer comprised 20% of the Company’s revenue. Concentrations of credit risk with respect to accounts receivable are typically limited due to the large number of customers comprising the Company’s customer base and because substantially all customers are located in the United States. At December 31, 2001, two customers comprised 16% and 72%, respectively, of the current and long-term accounts receivable balance with only the 16% customer being reportable in the segment for license fees and other professional services. At December 31, 2002, two customers comprised 18% and 26%, respectively, of the accounts receivable balance. At December 31, 2003, three customers comprised 32%, 18% and 10%, respectively, of the accounts receivable balance. Substantially all of the Company’s revenues are from sales transactions originating in the United States.

 

Cash Flows

 

The Company made cash payments for interest of approximately $386,000, $112,000, and $84,000 during the years ended December 31, 2001, 2002 and 2003, respectively.

 

The Company acquired property and equipment through the assumption of capital lease obligations amounting to $211,000, $15,000 and $0 during the years ended December 31, 2001, 2002 and 2003, respectively.

 

During 2001, the Company bought out approximately $2.3 million of capital leases. The Company borrowed $2.3 million at prime rate, from a bank to facilitate the buy out of the leases. The revolving loan commitment of $3.5 million, with a balance of $2,313,000 at December 31, 2003 is guaranteed by approximately $3.9 million of company funds invested in money market funds. The loan is described more fully in Note 10.

 

Comprehensive Income (Loss)

 

The Company has adopted the provisions of Statement of Financial Accounting Standards No. 130, “Reporting Comprehensive Income” (“SFAS No. 130”). Comprehensive income, as defined, includes all changes in equity during a period from non-owner sources. The Company’s only item of other comprehensive income during the years ended December 31, 2001, 2002 and 2003 was foreign currency translation.

 

Segment Reporting

 

As a result of the acquisition of EMAX in March 2000, the Company determined that it had separately reportable operating segments, as defined by Statement of Financial Accounting Standards No. 131, “Disclosures about Segments of an Enterprise and Related Information” (“SFAS No. 131”). SFAS No. 131 uses a management approach and designates the internal organization used by management for making operating decisions and assessing performance as the source of the Company’s reportable segments. SFAS No. 131 also requires disclosures about products and services, geographic areas, and major customers (see Note 17).

 

As discussed previously, in 2001 the Company ceased providing order-processing services to its customers. Accordingly, beginning January 1, 2002, the Company has only one reportable business segment—license fees and other professional services.

 

Net Income (Loss) Per Common Share

 

Basic net income (loss) per common share (“Basic EPS”) is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding. Diluted net income (loss) per common share (“Diluted EPS”) is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares and dilutive potential common share equivalents then outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. The calculation of the net loss per share available to common stockholders for the years ended December 31, 2001, 2002 and 2003 does not include potential shares of common stock equivalents of 555,577, 258,015 and 19,953 respectively, as their impact would be anti-dilutive.

 

In September 2001, the Board of Directors authorized a stock repurchase program. The program authorized the Company to purchase up to $5 million of common stock over the next twelve months from time to time in the open market or in privately negotiated transactions depending on market conditions. On August 28, 2002, the Company’s Board of Directors extended its prior authorization for an additional twelve months. As of December 31, 2003, the Company had purchased and placed in treasury 253,911 shares of its common stock at a cost of $1,258,948.

 

F-15


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Reclassifications

 

Certain prior period amounts have been reclassified to conform to the current period presentation.

 

Recent Accounting Pronouncements

 

In June 2002, the Financial Accounting Standards Board issued Statement of Financial Accounting Standard No. 146, “Accounting for Costs Associated with Exit or Disposal Activities” (“SFAS No. 146”). SFAS No. 146 nullifies Emerging Issues Task Force Issue No. 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring)” (“EITF No. 94-3”). SFAS No. 146 requires that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred. This is in contrast to EITF 94-3 that required recognition of a liability upon an entity’s commitment to an exit plan. SFAS No. 146 concludes that a commitment, by itself, does not create a present obligation meeting the definition of a liability. This statement establishes fair value as the objective for initial measurement of the liability. The provisions of SFAS No. 146 are effective for exit or disposal activities that are initiated after December 31, 2002. The adoption of SFAS No. 146 did not have any material impact on the Company’s financial statements or results of operations.

 

In November 2002, the Financial Accounting Standards Board issued Financial Accounting Series FASB Interpretation No. 45, “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others—an interpretation of FASB Statements No. 5, 57, and 107 and rescission of FASB Interpretation No. 34” (“FIN No. 45”). FIN No. 45 elaborates on the disclosures to be made by a guarantor in its interim and annual financial statements regarding its obligations under certain guarantees that it has issued. It also clarifies that a guarantor is required to recognize, at the inception of a guarantee, a liability for the fair value of the obligation undertaken in issuing the guarantee. The initial recognition and initial measurement provisions of FIN No. 45 are applicable on a prospective basis to guarantees issued or modified after December 31, 2002, irrespective of the guarantor’s fiscal year-end. The disclosure requirements are effective for financial statements of interim or annual periods ending after December 15, 2002. The interpretive guidance incorporated without change from Interpretation 34 continues to be required for financial statements for fiscal years ending after June 15, 1981—the effective date of Interpretation 34. The adoption of FIN No. 45 did not have any impact on the Company’s financial statements or results of operations. The required disclosures as of September 30, 2003 are presented in Note 15.

 

In December 2002, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 148, “Accounting for Stock-Based Compensation—Transition and Disclosure—an amendment of FASB Statement No. 123” (“SFAS No. 148”) which amends FASB Statement No. 123, “Accounting for Stock-Based Compensation,” to provide alternative methods of transition for an entity that voluntarily changes to the fair value based method of accounting for stock-based employee compensation. It also amends the disclosure provisions of that Statement to require prominent disclosure about the effects on reported net income of an entity’s accounting policy decisions with respect to stock-based employee compensation. SFAS No. 148 amends Accounting Principles Board Opinion No. 28, “Interim Financial Reporting,” to require prominent disclosure in interim financial information. The provisions of SFAS No. 148 are effective for financial statements for fiscal years ending after December 15, 2002 with the interim reporting provisions effective for reporting periods beginning after December 15, 2002. The adoption of SFAS No. 148 did not have any material impact on the Company’s financial statements or results of operations since the Company continues to utilize the provisions of Accounting Principles Board Opinion No. 25 “Accounting for Stock Issued to Employees,” rather than voluntarily change to the fair value based method. The required disclosures as of September 30, 2003 are presented in Note 2.

 

In April 2003, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 149 “Amendment of Statement 133 on Derivative Instruments and Hedging Activities” (“SFAS No. 149”). FASB Statements No. 133 “Accounting for Derivative Instruments and Hedging Activities” and No. 138, “Accounting for Certain Derivative Instruments and Certain Hedging Activities”, establish accounting and reporting standards for derivative instruments including derivatives embedded in other contracts (collectively referred to as derivatives) and for hedging activities. SFAS No. 149 amends Statement 133 for certain decisions made by the Board as part of the Derivatives Implementation Group (DIG) process. This Statement contains amendments relating to FASB Concepts Statement No. 7, “Using Cash Flow Information and Present Value in Accounting Measurements”, and FASB Statements No. 65, “Accounting for Certain Mortgage Banking Activities”, No. 91 “Accounting for Nonrefundable Fees and Costs Associated with Originating or Acquiring Loans and Initial Direct Costs of Leases”, No. 95, “Statement of Cash Flows”, and No. 126, “Exemption from Certain Required Disclosures about Financial Instruments for Certain Nonpublic Entities”. The provisions of SFAS No. 149 are effective for contracts entered into or modified after June 30, 2003. The adoption of SFAS No. 149 did not have any material impact on the Company’s financial statements or results of operations.

 

In January 2003, the Financial Accounting Standards Board issued Financial Accounting Series FASB Interpretation No. 46, “Consolidation of Variable Interest Entities, an Interpretation of ARB No. 51” (“FIN No. 46”). The primary objective of the Interpretation is to provide guidance on the identification of, and financial reporting for, entities over which control is achieved through

 

F-16


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

means other than voting rights; such entities are known as variable-interest entities (VIEs). FIN No. 46 has far-reaching effects and applies immediately to new entities created after January 31, 2003, as well as applies to existing entities in which an enterprise obtains an interest after that date. The provisions of FIN No. 46 are effective at the end of the first interim or annual period ending after December 15, 2003, to variable-interest entities in which an enterprise holds a variable interest that it acquired before February 1, 2003. FIN No. 46 is the guidance that determines (1) whether consolidation is required under the “controlling financial interest” model of Accounting Research Bulletin No. 51, “Consolidated Financial statements”, or other existing authoritative guidance, or, alternatively, (2) whether the variable-interest model under FIN No. 46 should be used to account for existing and new entities. The adoption of FIN No. 46 did not have any material impact on the Company’s financial statements or results of operations.

 

In May 2003, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 150 “Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity” (“SFAS No. 150”). SFAS No. 150 establishes standards for classification and measurement in the statement of financial position of certain financial instruments with characteristics of both liabilities and equity. It requires classification of a financial instrument that is within its scope as a liability (or an asset in some circumstances) because that financial instrument embodies an obligation of the issuer. SFAS No. 150 is effective for financial instruments entered into or modified after May 31, 2003, and otherwise shall be effective on July 1, 2003. The adoption of SFAS No. 150 did not have any material impact on the Company’s financial statements or results of operations.

 

Employee Stock Purchase Plan

 

During 2000, the Board of Directors reserved 146,666 shares of the Company’s common stock for issuance under the Employee Stock Purchase Plan (“ESPP”). The ESPP has two 24-month offering periods (each an “Offering Period”) annually, beginning May 1 and November 1, respectively. The first Offering Period under the ESPP ended on November 1, 2000. Eligible employees can elect to make deductions from 1% to 20% of their compensation during each payroll period of an Offering Period. Special limitations apply to eligible employees who own 5% or more of the outstanding common stock of the Company. None of the contributions made by eligible employees to purchase the Company’s common stock under the ESPP are tax deductible to the employees. Upon April 30 and October 31 (the “Purchase Date”) of each year, the total payroll deductions by an eligible employee for that six-month period will be used to purchase common stock of the Company at a price equal to 85% of the lesser of (a) the reported closing price of the Company’s common stock on the enrollment date of the Offering Period, or (b) the reported closing price of the common stock on the Purchase Date. In 2001, 2002 and 2003, the Company sold 16,630, 20,113, and 12,705 shares, respectively, of common stock pursuant to the employee stock purchase plan resulting in proceeds of $169,391, $117,671 and $39,733, respectively.

 

3. Acquisitions

 

Textco, Inc

 

On February 19, 2002, the Company purchased all of the outstanding stock of Textco, Inc. in exchange for the issuance of 29,165 shares of the Company’s common stock with a value of approximately $329,000 based on the average market price over the five-day period beginning two days before and ending two days after the acquisition date, cash payments in the amount of $393,000 (including $118,000 for acquisition-related expenses) and the assumption of $37,000 in net liabilities of Textco. This acquisition was accounted for using the purchase method of accounting under SFAS No. 141. The results of Textco’s operations have been included in the consolidated financial statements since the date of acquisition.

 

The merger agreement includes incentive payments upon achievement of cumulative revenue targets during the first year. Cash of $180,000 and 35,895 shares of common stock related to the incentive payments were placed in escrow. Since the cumulative revenue targets were achieved during 2002, the escrowed incentive payments have been paid, with the stock valued at $121,000. The additional $301,000 of purchase price was allocated to the developed software costs.

 

Of the total purchase price, $911,000 was allocated to the developed software costs and $106,000 was allocated to non-competition agreements. These assets are being amortized over a period of two to three years. An insignificant amount of purchase price was allocated to the tangible assets.

 

The purchase of Textco expanded SciQuest’s software product offerings into the early stages of drug discovery research via biological research software. Textco’s products are used by molecular biologists. Installations included commercial and academic research organizations and research universities. Textco’s two primary products, Gene Construction Kit and Gene Inspector, provide users with an intuitive, graphical technology for gene cloning projects, DNA sequence analyses and experiment tracking via electronic notebooks.

 

Effective May 31, 2003, the Company divested of its investment in Textco (see Note 18).

 

F-17


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Groton NeoChem

 

On March 18, 2002, the Company purchased substantially all of the assets of Groton NeoChem for cash payments in the amount of $423,000 (including $123,000 for acquisition-related expenses) and the assumption of $26,000 in net liabilities. This acquisition was accounted for using the purchase method of accounting under SFAS No. 141. The results of Groton NeoChem’s operations have been included in the consolidated financial statements since the date of acquisition.

 

The entire purchase price, approximately $449,000, was allocated to developed software costs, which are being amortized over the estimated useful life of the software, which is three years.

 

The Groton NeoChem solutions facilitate the capture, organization, management, analysis and presentation of data by integrating advanced software and analytical instrument technology.

 

Effective September 30, 2003, the Company divested of its investment in the Groton NeoChem assets (see Note 18).

 

HigherMarkets, Inc

 

On June 25, 2002, the Company purchased all of the outstanding stock of HigherMarkets, Inc. in exchange for the issuance of 86,957 shares of the Company’s common stock with a value of approximately $480,000 based on the average market price over the five-day period beginning two days before and ending two days after the acquisition date, cash payments of acquisition-related expenses of $42,000 and the assumption of $147,000 in net liabilities of HigherMarkets. This acquisition was accounted for using the purchase method of accounting under SFAS No. 141. The results of HigherMarkets’ operations have been included in the consolidated financial statements since the date of acquisition.

 

Of the total purchase price, $50,000 was allocated to fixed assets, $203,000 to the developed software costs and $293,000 to customer agreements. These assets are being amortized over a period of two to four years. In addition, approximately $95,000 of the total purchase price was allocated to cash and investments leaving $28,000 allocated to various current assets.

 

The purchase of HigherMarkets expands SciQuest’s software product offerings into the higher education marketplace via the HigherMarkets hosted procurement solutions designed to meet the unique needs of this industry. The HigherMarkets’ products are used by researchers and procurement departments of universities, colleges, research institutions and other post-secondary educational entities.

 

4. Investments

 

The aggregate fair values of investment securities at December 31, 2002 and 2003 along with unrealized gains and losses determined on an individual investment security basis are as follows:

 

Description    


  

Amortized

Cost


  

Gross

Unrealized

Gain (Loss)


  

Market

Value


December 31, 2002

                    

Short-term Investments:

                    

Certificates of Deposit

   $ 411,103    $ —      $ 411,103

Commercial paper

     2,000,000      —        2,000,000

Corporate bonds

     7,030,155      5,200      7,035,355

U.S. Government obligations

     1,000,000      —        1,000,000
    

  

  

     $ 10,441,258    $ 5,200    $ 10,446,458
    

  

  

Long-term Investments:

                    

Certificates of Deposit

   $ 125,800    $ —      $ 125,800

U.S. Government obligations

     9,129,041      2,428      9,141,469
    

  

  

     $ 9,254,841    $ 12,428    $ 9,267,269
    

  

  

 

F-18


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Description    


  

Amortized

Cost


  

Gross

Unrealized

Gain (Loss)


   

Market

Value


December 31, 2003

                     

Short-term Investments:

                     

Certificates of Deposit

   $ 245,000    $ —       $ 245,000

Corporate bonds

     2,012,784      596       2,013,380
    

  


 

     $ 2,257,784    $ 596     $ 2,258,380
    

  


 

Long-term Investments:

                     

U.S. Government obligations

   $ 3,889,000    $ (41,544 )   $ 3,847,456
    

  


 

     $ 3,889,000    $ (41,544 )   $ 3,847,456
    

  


 

 

5. Property and Equipment

 

Property and equipment consist of the following:

 

     December 31,

 
     2002

    2003

 

Furniture and equipment

   $ 1,788,012     $ 1,700,508  

Computer software and equipment

     9,695,953       9,819,302  

Leasehold improvements

     728,068       708,170  
    


 


Total costs

     12,212,033       12,227,980  

Less accumulated depreciation

     (9,477,920 )     (10,824,484 )
    


 


Property and equipment, net

   $ 2,734,113     $ 1,403,496  
    


 


 

Depreciation expense, including amortization of capitalized leases, for the years ended December 31, 2001, 2002 and 2003 was approximately $3,478,000 $2,953,000 and $1,618,000 respectively. The Company leases certain equipment under capital lease agreements. The cost of equipment under capital leases at December 31, 2002 and 2003 was approximately $193,000 and $0, respectively, with accumulated amortization of approximately $170,000 and $0, respectively.

 

6. Capitalized Software and Web Site Development Costs

 

Capitalized software and web site development costs represent the cost of developing software products for sale and the cost of developing the hosted applications for the Company’s licensed web sites, (i.e., internal use development costs). During 2001, 2002 and 2003, the Company capitalized development costs of $3,867,199, $2,056,995 and $659,113, respectively, related to software products for sale. The capitalized costs related to software products for sale was $16,937,846 and $16,050,757 at December 31, 2002 and 2003, respectively, with accumulated amortization of $8,977,884 and $11,409,901, respectively, resulting in net costs of $7,959,962 and $4,640,856, respectively. Related amortization expense, included in the cost of revenue and discontinued operations, was approximately $2,655,000, $4,712,000 (including $234,528 in discontinued operations) and $3,256,991 (including $234,528 in discontinued operations) for the years ended December 31, 2001, 2002 and 2003, respectively.

 

The Company capitalized internal use development costs, based on the provisions outlined in SOP No. 98-1, of $2,289,447, $258,493 and $1,287,336 during the years ended December 31, 2001, 2002 and 2003, respectively. Capitalized internal use development costs are $5,387,038 and $6,674,374 at December 31, 2002 and 2003, respectively, with accumulated amortization of $5,154,665 and $5,374,563 at December 31, 2002 and 2003, respectively, resulting in net costs of $232,373 and $1,299,811, respectively. Related amortization expense was approximately $2,974,000, $527,000 and $219,898 for the years ended December 31, 2001, 2002 and 2003, respectively.

 

7. Goodwill and Other Intangible Assets

 

        The Company adopted Statement of Financial Accounting Standards No. 142, “Goodwill and other Intangible Assets” (“SFAS No. 142”) effective January 1, 2002. This statement addresses accounting and reporting for acquired goodwill and intangible assets. In accordance with the transitional provisions of SFAS No. 142, the Company determined that the carrying value of goodwill and related assets exceeded their fair value. As a result, the Company recognized a charge to income of $38,257,357 ($9.74 per share) of goodwill impairment as the cumulative effect of a change in accounting principle during the first quarter of 2002. As of the end of each period presented, all of the Company’s intangible assets had definitive lives and were being amortized accordingly.

 

F-19


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

In March 2000, the Company acquired all of the outstanding common and preferred stock of EMAX Solution Partners, Inc. (EMAX) and allocated $22,000,000 of the purchase price to trademarks. Subsequently, the value of the trademarks was being amortized to expense over a three-year period. During the first quarter of 2002, the Company discontinued utilizing the EMAX trademarks, and accordingly, determined that the carrying value of the trademarks had been impaired. As a result, the Company recognized a charge to income of $7,155,914, the unamortized balance at March 31, 2002, ($1.84 per share) in the first quarter of 2002.

 

Other intangible assets are comprised of the following:

 

     December 31, 2002

    December 31, 2003

 
     Gross
Carrying
Amount


   Accumulated
Amortization


    Gross
Carrying
Amount


   Accumulated
Amortization


 

Non-compete agreements

   $ 106,000    $ (44,167 )   $ —      $ —    

Customer contracts

     390,379      (36,570 )     292,553      (109,710 )

Trademarks

     —        —         —        —    
    

  


 

  


Total

   $ 496,379    $ (80,737 )   $ 292,553    $ (109,710 )
    

  


 

  


 

    

Aggregate Expense for the Year

Ended December 31,


     2001

   2002

   2003

Non-compete agreements

   $ —      $ 44,167    $ 22,083

Customer contracts

     —        36,570      73,140

Customer acquisition costs

     199,998      —        —  

Trademarks

     7,333,333      1,833,333      —  
    

  

  

Total

   $ 7,533,331    $ 1,914,070    $ 95,223
    

  

  

 

Estimated Amortization Expense for the Years Ending December 31:

      

2004

   $ 73,140

2005

   $ 73,140

2006

   $ 36,563

2007

   $ —  

2008

   $ —  

 

Following is a schedule of the goodwill account activity by segment for each period presented:

 

     E-Commerce

    License fees
and other
professional
services


    Total

 

Balance at December 31, 2000

   $ 2,750,525     $ 69,894,300     $ 72,644,825  

Goodwill acquired

     —         —         —    

Amortization

     (660,126 )     (31,636,943 )     (32,297,069 )

Impairment losses

     (2,090,399 )     —         (2,090,399 )
    


 


 


Balance at December 31, 2001

     —         38,257,357       38,257,357  

Goodwill acquired

     —         —         —    

Amortization

     —         —         —    

Impairment losses

     —         (38,257,357 )     (38,257,357 )
    


 


 


Balance at December 31, 2002

     —         —         —    

Goodwill acquired

     —         —         —    

Amortization

     —         —         —    

Impairment losses

     —         —         —    
    


 


 


Balance at December 31, 2003

   $ —       $ —       $ —    
    


 


 


 

F-20


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Following is a reconciliation of the reported net loss to the adjusted net loss reflecting the impact of the adoption of SFAS No. 142 on all periods presented:

 

     For the Year Ended December 31,

 
     2001

    2002

    2003

 

Reported net loss:

                        

Reported net loss

   $ (82,837,105 )   $ (70,787,647 )   $ (16,590,276 )

Add back: Cumulative effect of accounting change for impairment of goodwill

     —         38,257,357       —    
    


 


 


Reported net loss before cumulative effect of accounting change

     (82,837,105 )     (32,530,290 )     (16,590,276 )

Add back: Goodwill amortization

     32,297,069       —         —    
    


 


 


Adjusted net loss

   $ (50,540,036 )   $ (32,530,290 )   $ (16,590,276 )
    


 


 


Loss per share-basic and diluted:

                        

Reported net loss

   $ (21.48 )   $ (18.03 )   $ (4.35 )

Add back: Cumulative effect of accounting change for impairment of goodwill

     —         9.74       —    
    


 


 


Reported net loss before cumulative effect of accounting change

     (21.48 )     (8.29 )     (4.35 )

Add back: Goodwill amortization

     8.37       —         —    
    


 


 


Adjusted net loss

   $ (13.11 )   $ (8.29 )   $ (4.35 )
    


 


 


 

8. Accrued Liabilities

 

Accrued liabilities are comprised of the following:

 

     December 31,

     2002

   2003

Accrued compensation

   $ 898,401    $ 1,704,708

Accrued consulting and professional services

     388,032      235,018

Accrued restructuring charges

     3,669,983      3,254,534

Accrued taxes payable

     438,829      341,911

Other

     285,690      88,785
    

  

Total

   $ 5,680,935    $ 5,624,956
    

  

 

9. Income Taxes

 

The Company had no income tax benefit or expense for the years ended December 31, 2001, 2002 and 2003. Significant components of the Company’s deferred tax assets and liabilities at December 31, 2002 and 2003:

 

     2002

    2003

 

Net operating loss carryforwards

   $ 64,132,434     $ 68,200,409  

Research and development

     662,734       822,734  

Allowance for doubtful accounts

     128,199       58,622  

Compensation accruals

     114,957       167,877  

Lease termination

     1,405,234       1,256,313  

Stock and warrant based compensation

     2,484,466       2,622,456  

Depreciation

     154,480       300,612  

Other

     184,227       272,678  
    


 


Total deferred tax assets

     69,266,731       73,701,701  

Valuation allowance for deferred tax assets

     (64,559,443 )     (70,605,728 )
    


 


Deferred tax assets

     4,707,288       3,095,973  
    


 


Intangibles assets

     (311,054 )     —    

Accrual to cash

     (1,954,403 )     (977,202 )

Deferred revenue

     (63,582 )     —    

Capital development costs

     (2,378,249 )     (2,118,771 )
    


 


Total deferred tax liabilities

     (4,707,288 )     (3,095,973 )
    


 


Net deferred tax liability

   $ —       $ —    
    


 


 

F-21


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

The Company has provided a valuation allowance against the balance of its deferred tax assets since realization of these benefits cannot be reasonably assured. The change in valuation allowance was an increase of $19,924,313, $12,457,168 and $6,046,285 for the years ended December 31, 2001, 2002 and 2003, respectively. The change primarily relates to additional operating losses in those years.

 

As of December 31, 2003, the Company had federal and state net operating loss carryforwards of approximately $182,458,000 and $133,431,000, respectively. These net operating loss carryforwards begin to expire in 2012. The utilization of the federal net operating loss carryforwards may be subject to limitation under the rules regarding a change in stock ownership as determined by the Internal Revenue Code. If the Company’s utilization of its net operating loss carryforwards is limited and the Company has taxable income which exceeds the permissible yearly net operating loss utilization, the Company would incur a Federal income tax liability even though its net operating loss carryforwards exceed its taxable income.

 

Taxes computed at the statutory federal income tax rate of 34% are reconciled to the provision (benefit) for income taxes as follows:

 

    

December 31,

2001


   

December 31,

2002


   

December 31,

2003


 

Effective rate

     (0 )%     (0 )%     (0 )%

United States federal tax at statutory rate

   $ (28,164,616 )   $ (24,067,799 )   $ (5,640,694 )

State taxes (net of federal benefit)

     (3,267,114 )     (1,330,150 )     (727,320 )

Change in valuation allowance

     19,924,313       12,457,168       6,046,285  

Deferred tax liabilities on acquisitions

     —         132,729          

Goodwill amortization or impairment

     11,691,739       13,007,501       —    

Other nondeductible expenses

     23,054       13,889       77,150  

Research and development credits

     (305,218 )     (208,213 )     (160,000 )

Expiration of foreign net operating loss

     —         —         193,599  

Other

     97,842       (5,125 )     210,980  
    


 


 


Provision (benefit) for income tax

   $ —       $ —       $ —    
    


 


 


 

10. Notes Payable

 

In November 2001, the Company entered into a term loan with a commercial bank for $2,300,000. The proceeds were used to buyout various leases with interest rates of up to 32%. The interest rate on the term loan was at the lender’s prime rate. The loan was fully collateralized by a money market investment account held with the lender. Accrued interest and principal payments were due monthly through the final maturity date of January 1, 2004.

 

During 2002, the Company restructured the term loan to a two-year revolving line of credit with a commitment amount of $2.5 million. The line’s final maturity date was August 5, 2004. Interest was payable monthly at the lender’s prime rate. The loan commitment was fully collateralized with restricted investments held by the lender. Other conditions include maintaining the Company’s primary depository account with the lender.

 

During September 2003, the Company negotiated a modification and extension of its revolving line of credit with an increased commitment amount of $3.5 million. The line, which has a balance of $2,312,833 at December 31, 2003, is due on January 3, 2006. Interest is payable monthly at the lender’s prime rate (4.0% at December 31, 2003). The loan commitment is collateralized with restricted investments in the amount of $3,889,000 at December 31, 2003. The funds are available for working capital uses and no other significant conditions are applicable.

 

11. Stock Options and Warrants

 

Stock Options

 

In 1997, the Company adopted the SciQuest, Inc. Stock Option Plan (the “Plan”), which currently provides for the grant of up to 274,141 employee stock options. Stock options granted under the Plan are for periods not to exceed ten years. In December 1999, the Company adopted the SciQuest, Inc. 1999 Stock Option Plan, which provides, as adjusted by the shareholders in 2001, for the additional grant of up to 1,047,333 employee stock options. In 2000, the Company adopted the SciQuest, Inc. EMAX Stock Option Plan, which provides for the additional grant of up to 51,853 employee stock options. Options granted under the plans during the years ended December 31, 2001, 2002 and 2003 generally vest in periods between three and five years as determined by the board of directors, although certain grants have been vested immediately upon the grant of the option.

 

F-22


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

A summary of the status of the Plans as of December 31, 2001, 2002 and 2003 and changes during the years then ended is presented below:

 

     Year Ended December 31,

     2001

   2002

   2003

    

Shares

Underlying

Options


   

Weighted

Average

Exercise

Price


  

Shares

Underlying

Options


   

Weighted

Average

Exercise

Price


  

Shares

Underlying

Options


   

Weighted

Average

Exercise

Price


Outstanding at beginning of year

   515,949     $ 47.10    702,183     $ 19.05    679,220     $ 15.68

Granted

   604,847       12.30    141,320       9.08    205,079       3.80

Exercised

   (27,430 )     1.35    (15,835 )     1.95    (467 )     1.38

Forfeited

   (391,183 )     46.95    (148,448 )     26.55    (202,228 )     13.36
    

 

  

 

  

 

Outstanding at end of period

   702,183     $ 19.05    679,220     $ 15.68    681,604     $ 12.83
    

 

  

 

  

 

 

All incentive stock options granted during the years ended December 31, 2001, 2002 and 2003 were granted with an exercise price equal to the fair value of the underlying common stock on the grant date, as determined by the board of directors.

 

On December 13, 2000, the Board of Directors approved a repricing of approximately 156,400 non-officer employee stock options to the closing price of $15.9375. Accordingly, the Company recognizes adjustments to the related deferred compensation for changes in the intrinsic value of the repriced options at each balance sheet date. In 2001, 2002 and 2003, the repricing resulted in no additional deferred compensation or amortization of expense due to the December 31, 2001, 2002 and 2003 closing prices being below the revised exercise price.

 

The following table summarizes information about the Company’s outstanding stock options at December 31, 2003:

 

Range of Exercise Prices    


  

Number of

Options

Outstanding


  

Weighted

Average

Contractual

Life


  

Weighted

Average

Exercise

Price


  

Number of

Options

Exercisable


  

Weighted

Average

Exercise

Price


$1.38-3.26

   2,920    6.45    $ 2.39    1,420    $ 1.46

$3.68

   66,667    9.06      3.68    —        —  

$3.75-$4.95

   147,477    8.71      4.02    23,864      4.09

$5.19-$7.50

   108,193    7.68      6.15    75,478      6.22

$7.70-$13.50

   52,846    7.62      11.11    22,334      11.38

$14.06

   120,000    7.16      14.06    90,001      14.06

$15.94

   161,967    6.86      15.94    126,119      15.94

$23.10-$73.76

   16,936    5.61      60.97    16,580      61.04

$117.95-$378.65

   4,598    5.99      292.50    4,598      292.50
    
  
  

  
  

$1.38-378.65

   681,604    7.68    $ 12.83    360,394    $ 17.91
    
  
  

  
  

 

Warrants

 

At December 31, 2002 and 2003, the Company had 106,743 and 102,133 respectively, of warrants outstanding, with 102,133 warrants exercisable at December 31, 2003, to purchase the Company’s common stock at prices ranging from $0.075 to $69.98, which includes the warrants issued to strategic partners discussed in Note 14. These warrants expire at various dates between 2004 and 2007.

 

12. Commitments and Contingencies

 

The Company leases office space and certain equipment under noncancellable operating leases. The Company did not have any capital lease obligations at December 31, 2003. Future minimum lease payments required under leases at December 31, 2003 are as follows:

 

    

Operating

Leases


 

2004

   $ 2,194,701  

2005

     1,727,201  

2006

     1,073,469  

2007

     1,083,398  

2008

     1,093,326  

Thereafter

     2,528,727  
    


Total minimum lease payments

   $ 9,700,822 *
    



* Future minimum operating lease payments have not been reduced by future minimum sublease rentals of $855,000.

 

F-23


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Rent expense recognized under operating leases totaled approximately $1,685,000, $1,061,000 and $757,000 for the years ended December 31, 2001, 2002 and 2003, respectively.

 

During 1999, the Company entered into a lease agreement for additional office space for its home office providing a total of 93,000 square feet into the year 2005. During 2001, the Company entered into a lease for 39,000 square feet of office space for its Pennsylvania operation. The lease, which is for a period of 10 years, commenced in March 2001.

 

13. Legal Proceedings

 

SciQuest and three of its officers were named as defendants in a lawsuit filed on September 10, 2001 in the United States District Court, Southern District of New York, captioned Patricia Figuerido v. Sciquest.com, Inc, No. 01 CV 8467. The case subsequently was consolidated for pretrial purposes with approximately 1,000 other lawsuits filed against more than 300 other issuers, certain of their officers and directors, and the underwriters of their initial public offerings, under the caption In re Initial Public Offering Securities Litigation, 21 MC 92 (SAS). After the cases were consolidated, plaintiffs filed a Master Complaint and 309 consolidated amended complaints related to each issuer defendant’s offering. The consolidated amended complaint in In re Sciquest.com, Inc. Initial Public Offering Securities Litigation, No. 01 Civ. 7415, purports, on behalf of a putative class of purchasers of the Company’s common stock from its initial public offering through December 6, 2000, to state claims under the Securities Act of 1933 and under the Securities Exchange Act of 1934 against SciQuest and seven investment banking firms who either served as underwriters, or are the successors in interest to underwriters, of the Company’s initial public offering. Separate claims against the underwriters only also have been brought under the Securities Act and the Exchange Act. The complaint alleges that the prospectus used in the Company’s initial public offering contained material misstatements or omissions regarding the underwriters’ allocation practices and compensation in connection with the initial public offering and also alleges that the underwriters manipulated the aftermarket for the Company’s common stock. In October 2002, the claims against the Company’s officers were dismissed without prejudice. In February 2003, the court denied SciQuest’s motion to dismiss the action against it. On July 1, 2003, a Special Committee of the Board acting on behalf of the Company authorized the Company to enter into a definitive settlement agreement to be prepared under the terms outlined in a Memorandum of Understanding. The anticipated settlement will be subject to court approval following notice to class members and a fairness hearing. Until final approval of the settlement by the court, the Company intends to continue its vigorous defense against the action that originally sought an unspecified amount of damages, together with interest, costs and attorneys’ fees. It is too early in this matter to reasonably predict the probability of the outcome or to estimate a range of possible losses. Future losses may have a material adverse effect on the Company’s consolidated financial position, liquidity or consolidated results of operations.

 

During 2001, a customer filed an action seeking a declaratory judgment that its license entitled it to permit non-customer employees to use the Company’s licensed software. In addition, the complaint alleges breach by the Company of an agreement pursuant to which the Company was to upgrade the software to a newer version. The complaint seeks damages alleged to exceed $1,000,000. The litigation arises out of the Company’s discovery that the customer had permitted non-customer employees to use the software. After attempts proved unsuccessful to amicably resolve the dispute, the Company suspended work on the upgrade and the customer failed to pay for the work performed. The Company intends to vigorously defend the action and has asserted its counterclaims seeking damages in excess of $2,000,000 for copyright infringement and breach of contract and to recover the amounts due for work previously billed, but unpaid. In March 2004, the parties, under the guidance of the magistrate, agreed to a settlement structure of $450,000 to be paid to SciQuest with a release of all other claims. Currently the parties are drafting the definitive settlement documents for execution.

 

14. Strategic Relationships

 

In October, November and December 1999, the Company entered into strategic relationships with a number of key suppliers and buyers of scientific products. As a part of these arrangements, the Company issued to these companies 546,890 warrants to purchase the Company’s common stock at an exercise price of $0.075 per share of which 7,500 warrants were issued and outstanding at December 31, 2003. During 2001 and 2002, warrants representing 30,522 and 455,482 shares, respectively, of common stock were cancelled. These cancellations will not have any effect on net stockholders’ equity. Future amortization costs will be reduced by an undetermined amount. At December 31, 2002 and 2003, the Company had deferred customer acquisition costs of $3,255,394 and $3,256,705, respectively, with accumulated amortization of $3,250,186 and $3,256,705, respectively, related to these warrants. The amount of deferred customer acquisition costs will be adjusted in future reporting periods based on changes in the fair value of the warrants until such date as the warrants are fully vested and non-forfeitable. Deferred customer acquisition costs are amortized to operating expense over the term of the related contractual relationship, which in the case of the buyer agreements is three years and in the case of the supplier agreements is four or five years, using a cumulative catch-up method. The Company recognized $2,100,123, $(383,990) and $6,519 in stock-based non-cash customer acquisition expense (benefit) during the years ended December 31, 2001, 2002 and 2003, respectively, related to the amortization of deferred customer acquisition costs. In 2001, this amount included approximately $200,000 of amortization of prepaid customer acquisition fees.

 

F-24


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

In addition, in 1999, the Company agreed to issue to certain major enterprise buyers additional incentive warrants, the number of which was to be based on each purchaser’s volume of purchases through the Company’s market place during the years 2000, 2001 and 2002. These incentive warrants were to be issued annually on February 15 through 2003, at an exercise price of $16 per share, and were to be exercisable upon issuance. As the Company discontinued the order processing services in May 2001, there have been no additional warrants earned subsequent to such date.

 

Based on purchasing volume during the year ended December 31, 2000, incentive warrants to purchase approximately 7,733 shares of common stock were issued on February 15, 2001, resulting in a non-cash charge to revenue and the recognition of additional paid-in capital of approximately $52,000 representing the estimated fair value of the warrants determined by using the Black-Scholes valuation model at the issuance date. Until they were forfeited in 2002, the value of these incentive warrants were adjusted to their estimated fair value at each balance sheet date with the adjustment being charged to operating expense. For the years ended December 31, 2001 and 2002, this adjustment resulted in a benefit of approximately $45,000 and $7,000, respectively. No incentive warrants were granted related to purchases during 2001 or 2002, and none will be granted related to 2003 purchases due to the change in the Company’s business model.

 

15. Related Party Transactions

 

In February 2002, the Company guaranteed an $80,000 loan for Mr. M. Scott Andrews, a member of the Board of Directors and co-founder. The loan bears interest at prime rate and becomes payable in full in February 2004. The Company has agreed to reimburse Mr. Andrews for interest paid on this loan. The transaction was approved by a majority of the Company’s disinterested directors. Mr. Andrews repaid the entire loan in February 2004, and consequently the Company has been released from its guarantee on this loan arrangement.

 

The Sarbanes-Oxley Act of 2002 prohibits companies from extending credit or arranging for the extension of credit for any director or executive officer in the form of a personal loan. Credit arrangements that were in place prior to this act may be maintained, but not renewed. The Company believes that it is fully compliant with this act and did not renew any guarantees after the maturity of the loan referenced above.

 

In September 2003, the Company renewed a partial guarantee of a $440,000 real estate loan to a co-founder secured with a certificate of deposit in the amount of $245,000. The loan bears interest at prime rate and becomes payable in full in September 2004. The transaction was approved unanimously by the Company’s Board of Directors all of whom were disinterested with respect to this transaction.

 

16. Restructuring

 

In June 2001, the Company announced a restructuring of the business to essentially eliminate outsourced procurement services. The restructuring included the elimination of certain unprofitable business lines and a resultant reduction in workforce of approximately one-half of the employees located in the United States. The total restructuring charge was $10.7 million and included approximately $1.6 million for employee separation benefits, $6.7 million of asset writedowns and approximately $2.4 million of other costs and lease obligations relating to the unprofitable business lines to be eliminated. This restructuring has been concluded except for the lease obligations.

 

Due to the additional excess occupancy costs resulting from both an increase in the amount of unutilized rental space and an increase in the estimated number of months before receiving anticipated sublease proceeds because of the depressed local commercial real estate markets, the Company reevaluated the 2001 provision for excess office capacity and increased the charge for restructuring by $2.9 million during 2002.

 

During the first quarter of 2003, the Company began refocusing resources to support its procurement product platform and reducing costs in other areas, which resulted in an elimination of approximately 50 full-time positions by the end of the second quarter of 2003. This reduction in personnel resulted in the recognition of severance expense and additional excess office space. Also during 2003, new subleases and adjustments to previous subleases resulted in adjustments to the restructuring liability and charges to restructuring expense.

 

F-25


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

The following table summarizes information about the Company’s restructuring plans:

 

    

Restructuring

Plans


  

Additional
Restructuring

Expenses


  

Impairment

Expenses and

Charges

to Liability


  

Remaining

Liability at

December 31,

2002


Number of employees

     108      —        108      —  
    

  

  

  

Involuntary termination benefits

   $ 1,630,293    $ —      $ 1,630,293    $ —  

Other costs, primarily lease obligations

     2,346,239      2,900,000      1,576,256      3,669,983

Write-down of net assets of business lines to be eliminated

     6,673,468      —        6,673,468      —  
    

  

  

  

Total

   $ 10,650,000    $ 2,900,000    $ 9,880,017    $ 3,669,983
    

  

  

  

 

    

Liability at

December 31,

2002


  

Additional
Restructuring

Expenses


  

Impairment

Expenses and

Charges

to Liability


  

Remaining

Liability at

December 31,

2003


Number of employees

     —        36      36      —  
    

  

  

  

Involuntary termination benefits

   $ —      $ 380,000    $ 380,000    $ —  

Other costs, primarily lease obligations

     3,669,983      902,000      1,317,449      3,254,534
    

  

  

  

Total

   $ 3,669,983    $ 1,282,000    $ 1,697,449    $ 3,254,534
    

  

  

  

 

17. Business Segment Data

 

During 2001, as a result of the acquisition of EMAX, the Company operated in two business segments—e-commerce transactions and license fees and other professional services. As discussed in Note 2, the Company operated in only one business segment in 2002 as a result of management’s decision to evolve the business into a software and related services provider. Accordingly, no segment data has been provided as of and for the years ended December 31, 2002 and 2003, since the only remaining segment is license fees and other professional services. Substantially all of the Company’s operations are in the United States.

 

     Year Ended December 31, 2001

 
     E-Commerce

   

License fees

and other

professional

services


    Consolidated

 

Revenues—external customers

   $ 16,230,172     $ 6,981,255     $ 23,211,427  

Depreciation and amortization

   $ 6,667,813     $ 42,111,590     $ 48,779,403  

Non-cash stock based compensation and customer acquisition costs

   $ 2,593,109     $ 583,066     $ 3,176,175  

Operating loss

   $ (39,873,045 )   $ (45,657,646 )   $ (85,530,691 )

Interest revenue

     3,025,770       53,996       3,079,766  

Interest expense

     (255,763 )     (130,417 )     (386,180 )
    


 


 


Loss before income taxes

     (37,103,038 )     (45,734,067 )     (82,837,105 )

Income tax benefit

     —         —         —    
    


 


 


Net loss

   $ (37,103,038 )   $ (45,734,067 )   $ (82,837,105 )
    


 


 


Capital expenditures

   $ 3,397,887     $ 4,161,342     $ 7,559,229  
    


 


 


Total assets

   $ 55,185,661     $ 60,739,896     $ 115,925,557  
    


 


 


 

18. Divestitures

 

Effective May 31, 2003, the Company sold all of the outstanding shares of Textco, Inc. to the original owners in exchange for all of the 65,060 shares of SciQuest common stock originally issued in February 2002 as part of the acquisition by SciQuest and a secured interest-free promissory note in the amount of $180,000, which is due in monthly installments through May 30, 2004. The fair value of the note using an imputed interest rate of 6.95% equals $172,484. The common stock was valued at $267,007 based on the average market price over the five-day period beginning two days before and ending two days after the sale date. The sale resulted in a loss on disposal of $247,417, ($0.06 per share) during the second quarter of 2003.

 

F-26


SciQuest, Inc.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

The results of operations of the business unit are shown as discontinued operations for all periods presented. The following is the condensed financial information for the Textco business unit for the years ended December 31, 2002 and 2003.

 

     Year Ended December 31,

 
     2002

    2003

 

Revenue

   $ 700,051     $ 244,094  

Gross profit

   $ 413,982     $ (13,207 )

Operating expenses

   $ 683,523     $ 187,553  

Income (loss) from operations

   $ (269,541 )   $ (200,760 )

Loss on disposal

     —         (247,417 )
    


 


Total income (loss) from discontinued operations

   $ (269,541 )   $ (448,177 )
    


 


 

Effective July 2003, the Company divested the net assets related to BioSupplyNet and recognized a gain on the transaction of $170,000.

 

Effective September 2003, the Company divested the net assets related to Groton NeoChem and recognized a loss of $165,000.

 

19. Reverse Stock Split

 

On April 30, 2003, the shareholders authorized the Board of Directors to amend the Company’s certificate of incorporation to effect a reverse stock split at one of three ratios. Subsequently, the Board of Directors approved a reverse stock split in the ratio of one share for every seven and one-half shares outstanding. The reverse stock split was effective as of May 20, 2003. As a result, the number of shares outstanding on May 20, 2003 was reduced from 28,966,037 to 3,862,138. The Company repurchased the related fractional shares.

 

All share and per share information has been adjusted to give effect to the reverse stock split for all periods presented, including all references throughout the financial statements and accompanying notes.

 

F-27


SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, SciQuest, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

SciQuest, Inc.

(Registrant)

By:

 

/S/    STEPHEN J. WIEHE        


   

Stephen J. Wiehe

Chief Executive Officer

 

Date: March 25, 2004

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Signature


  

Title


 

Date


/s/    STEPHEN J. WIEHE        


Stephen J. Wiehe

  

Chief Executive Officer (Principal Executive Officer) and Director

  March 25, 2004

/s/    DAVID R. POUCHER        


David R. Poucher

  

Controller (Principal Financial Officer)

  March 25, 2004

/s/    M. SCOTT ANDREWS        


M. Scott Andrews

  

Director

  March 25, 2004

/s/    DANIEL F. GILLIS        


Daniel F. Gillis

  

Director

  March 25, 2004

/s/    H. ALEXANDER HOLMES        


H. Alexander Holmes

  

Director

  March 25, 2004

/s/    LLOYD SEGAL        


Lloyd Segal

  

Director

  March 25, 2004

/s/    LOUIS M. SHERWOOD        


Louis M. Sherwood

  

Director

  March 25, 2004